<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZENATANEÂ - isotretinoinÂ capsule, gelatin coatedÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1><span class="Bold">Isotretinoin Capsules USP</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_abf298c6-7024-0212-dfb1-029fc27933ce"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></span></p>
<p><img alt="figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=517810a4-76bb-4739-893f-1f2ba94a5d0c&amp;name=figure.jpg"></p>
<p><span class="Bold">DO NOT GET PREGNANT</span></p>
</div>
<div class="Warning">
<a name="BOXED_WARNING"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">CONTRAINDICATIONS AND WARNINGS </span></p>
<p><span class="Bold"></span><span class="Bold"><span class="Bold">ZenataneÂ™</span> must not be used by female patients who are or may become pregnant. There is an extremely high risk that severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> will result if pregnancy occurs while taking <span class="Bold">ZenataneÂ™</span> in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected. </span></p>
<p><span class="Bold"></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> which have been documented following <span class="Bold">ZenataneÂ™</span> exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>, and <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature births</span> have been reported. </span></p>
<p><span class="Bold"></span><span class="Bold">Documented external abnormalities include: skull abnormality; ear abnormalities (including <span class="product-label-link" type="condition" conceptid="381384" conceptname="Congenital absence of external ear">anotia</span>, micropinna, small or absent external auditory canals); eye abnormalities (including <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>); facial dysmorphia; <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>. Documented internal abnormalities include: CNS abnormalities (including cerebral abnormalities, cerebellar malformation, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span>, <span class="product-label-link" type="condition" conceptid="381114" conceptname="Microcephalus">microcephaly</span>, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred with certain of the abnormalities previously noted.</span></p>
<p><span class="Bold">If pregnancy does occur during treatment of a female patient who is taking <span class="Bold">ZenataneÂ™</span> , <span class="Bold">ZenataneÂ™</span> must be discontinued immediately and she should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling.</span><span class="Bold">Â </span><span class="Bold"></span></p>
<p><span class="Bold">Special Prescribing Requirements</span><span class="Bold">Â </span></p>
<p><span class="Bold"></span><span class="Bold">Because of <span class="Bold">ZenataneÂ™</span> <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> and to minimize fetal exposure, <span class="Bold">ZenataneÂ™</span> is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. This program is called iPLEDGEâ„¢. <span class="Bold">ZenataneÂ™</span> must only be prescribed by prescribers who are registered and activated with the iPLEDGE program. ZenataneÂ™ must only be dispensed by a pharmacy registered and activated with iPLEDGE, and must only be dispensed to patients who are registered and meet all the requirements of iPLEDGE (see <a href="#PRECAUTIONS">PRECAUTIONS</a>).</span></p>
<p></p>
<p><span class="Bold">Table 1 Monthly Required iPLEDGE Interactions</span></p>
<a name="if2ed4885-08a1-433d-87e6-814755939534"></a><table border="0" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td colspan="1" rowspan="1" valign="top"></td>
<td colspan="1" rowspan="1" valign="top">
<span class="Bold">Female Patients of</span><br><span class="Bold">Childbearing Potential</span>Â </td>
<td colspan="1" rowspan="1" valign="top">
<span class="Bold">Male Patients, And Female</span><br><span class="Bold">Patients Not of Childbearing</span><span class="Bold">Potential</span>
</td>
</tr>
<tr><td colspan="3" rowspan="1" valign="top"><span class="Bold">PRESCRIBER </span></td></tr>
<tr>
<td colspan="1" rowspan="1">Confirms patient counseling </td>
<td colspan="1" rowspan="1">X</td>
<td colspan="1" rowspan="1">X</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Enters the 2 contraception methods </td>
<td colspan="1" rowspan="1" valign="top">X</td>
<td colspan="1" rowspan="1" valign="top">Â </td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">chosen by the patient </td>
<td colspan="1" rowspan="1" valign="top">Â </td>
<td colspan="1" rowspan="1" valign="top">Â </td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Enters pregnancy test results </td>
<td colspan="1" rowspan="1" valign="top">X</td>
<td colspan="1" rowspan="1" valign="top">Â </td>
</tr>
<tr><td colspan="3" rowspan="1" valign="top"><span class="Bold">PATIENT </span></td></tr>
<tr>
<td colspan="1" rowspan="1">Answers educational questions before </td>
<td colspan="1" rowspan="1">X</td>
<td colspan="1" rowspan="1" valign="top">Â </td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">every prescription </td>
<td colspan="1" rowspan="1" valign="top">Â </td>
<td colspan="1" rowspan="1" valign="top">Â </td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Enters 2 forms of contraception </td>
<td colspan="1" rowspan="1" valign="top">X</td>
<td colspan="1" rowspan="1" valign="top">Â </td>
</tr>
<tr><td colspan="3" rowspan="1" valign="top"><span class="Bold">PHARMACIST </span></td></tr>
<tr class="Last">
<td colspan="1" rowspan="1">Contacts system to get an authorization </td>
<td colspan="1" rowspan="1">X</td>
<td colspan="1" rowspan="1">X</td>
</tr>
</tbody></table>
<p></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="_4840a903-2bb8-3016-4ebd-ccb60b2603c8"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Isotretinoin USP, a retinoid, is available as ZenataneÂ™ (isotretinoin capsules USP) in 10 mg, 20 mg and 40 mg soft gelatin capsules for oral administration. Each capsule contains butylated hydroxyanisole, edetate disodium, hydrogenated vegetable oil (Type-I and Type-II), medium chain triglyceride, refined soybean oil and white wax. Gelatin capsules contain gelatin, glycerin, methylparaben, propyl paraben, lake blend blue(LB-332) containing D&amp;C Yellow No.10, FD&amp;C Blue No.1 (for 10 mg), lake blend redÂ  (LB-1574) containing D&amp;C Red No.27, D&amp;C Red No.30 (for 20 mg), lake blend green (LB-333)Â  containing D&amp;C Yellow No.10, FD&amp;C Blue No.1 (for 40 mg), lake blend white (TLB-1774) containing FD&amp;C Blue No.2, titanium dioxide, and opacode black S-1-27794 containing iron oxide black, N-butyl alcohol, propylene glycol, industrial methylene spirit and shellac.Â  </p>
<p>Chemically, isotretinoin is 13-cis-retinoic acid and is related to both retinoic acid and retinol (vitamin A). It is a yellow or light orange crystalline powder with a molecular weight of 300.44. It is practically insoluble in water, soluble in chloroform; sparingly soluble inÂ  alcohol, in isopropyl alcohol and in polyethylene glycon 400. The structural formula is:</p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=517810a4-76bb-4739-893f-1f2ba94a5d0c&amp;name=structure.jpg">Â </p>
<p></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL_PHARMACOLOGY"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Isotretinoin is a retinoid, which when administered in pharmacologic dosages of 0.5 to 1 mg/kg/day (see <span class="Bold"><a href="#_2702a7c7-239a-ff77-7cdc-18982b805c7d">DOSAGE </a><a href="#_2702a7c7-239a-ff77-7cdc-18982b805c7d">AND</a><a href="#_2702a7c7-239a-ff77-7cdc-18982b805c7d">ADMINISTRATION</a></span>), inhibits sebaceous gland function and keratinization. The exact mechanism of action of isotretinoin is unknown.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="_83fbcba3-2e60-4ef0-0065-55fe823aaaa5"></a><a name="section-3.1"></a><p></p>
<h2><span class="Bold">Nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></span></h2>
<p class="First">Clinical improvement in nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and is related to the dose and duration of treatment with ZenataneÂ™, and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation.<span class="Sup">1 </span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="_9c95c40f-6fa3-fc49-c8eb-c670456de3f2"></a><a name="section-3.2"></a><p></p>
<h2><span class="Bold">Pharmacokinetics</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="_526f4d99-2baa-bcda-7a9a-52a8b7f0068f"></a><a name="section-3.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Due to its high lipophilicity, oral absorption of isotretinoin is enhanced when given with a high fat meal. In a crossover study, 74 healthy adult subjects received a single 80 mg oral dose (2 x 40 mg capsules) of ZenataneÂ™ under fasted and fed conditions. Both peak plasma concentration (C<span class="Sub">max</span>) and the total exposure (AUC) of isotretinoin were more than doubled following a standardized high-fat meal when compared with ZenataneÂ™ given under fasted conditions (see <span class="Bold">Table 2</span>). The observed elimination half-life was unchanged. This lack of change in half-life suggests that food increases the bioavailability of isotretinoin without altering its disposition. The time to peak concentration (T<span class="Sub">max</span>) was also increased with food and may be related to a longer absorption phase. Therefore, ZenataneÂ™ should always be taken with food (see <span class="Bold"><a href="#_2702a7c7-239a-ff77-7cdc-18982b805c7d">DOSAGE</a><a href="#_2702a7c7-239a-ff77-7cdc-18982b805c7d">AND ADMINISTRATION</a></span>). Clinical studies have shown that there is no difference in the pharmacokinetics of isotretinoin between patients with nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> and healthy subjects with normal skin.</p>
<p><span class="Bold">Table 2 Pharmacokinetic Parameters of Isotretinoin Mean (%CV), N=74)</span></p>
<a name="ia65aaa4c-b392-410d-8bcd-826af1814cb7"></a><table border="1" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">ZenataneÂ™ </span><br><span class="Bold">2 x 40 mg </span><br><span class="Bold">Capsules</span>
</td>
<td>
<span class="Bold">AUC</span><span class="Sub">0-âˆž</span><br><span class="Bold">(ng</span>â‹…<span class="Bold">hr/mL)</span>
</td>
<td>
<span class="Bold">C<span class="Sub">max</span></span><br><span class="Bold">(ng/mL)</span>
</td>
<td>
<span class="Bold">T</span><span class="Sub">max </span><br><span class="Bold">(hr)</span>
</td>
<td>
<span class="Bold">t<span class="Sub">1/2</span><br></span><span class="Bold">(hr)</span>
</td>
</tr>
<tr>
<td>Fed*</td>
<td>10,004 (22%)</td>
<td>862 (22%)</td>
<td>5.3 (77%)</td>
<td>21 (39%)</td>
</tr>
<tr class="Last">
<td>Fasted</td>
<td>3,703 (46%)</td>
<td>301 (63%)</td>
<td>3.2 (56%)</td>
<td>21 (30%)</td>
</tr>
</tbody></table>
<p>*Eating a standardized high fat meal<span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ebfafae4-388d-e8fc-a65e-fb017240e026"></a><a name="section-3.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Isotretinoin is more than 99.9% bound to plasma proteins, primarily albumin. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_f321044c-ecc1-792a-f4a8-0e0fc012ebfe"></a><a name="section-3.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Following oral administration of isotretinoin, at least three metabolites have been identified in human plasma: 4-oxo-isotretinoin, retinoic acid (tretinoin), and 4-oxo-retinoic acid (4-oxotretinoin). Retinoic acid and 13-cis-retinoic acid are geometric isomers and show reversible interconversion. The administration of one isomer will give rise to the other. Isotretinoin is also irreversibly oxidized to 4-oxo-isotretinoin, which forms its geometric isomer 4-oxo-tretinoin. </p>
<p>After a single 80 mg oral dose of ZenataneÂ™ to 74 healthy adult subjects, concurrent administration of food increased the extent of formation of all metabolites in plasma when compared to the extent of formation under fasted conditions.</p>
<p>All of these metabolites possess retinoid activity that is in some in vitro models more than that of the parent isotretinoin. However, the clinical significance of these models is unknown. After multiple oral dose administration of isotretinoin to adult <span class="product-label-link" type="condition" conceptid="4028013" conceptname="Cystic acne">cystic acne</span> patients (â‰¥18 years), the exposure of patients to 4-oxo-isotretinoin at steady-state under fasted and fed conditions was approximately 3.4 times higher than that of isotretinoin.</p>
<p>In vitro studies indicate that the primary P450 isoforms involved in isotretinoin metabolism are 2C8, 2C9, 3A4, and 2B6. Â Isotretinoin and its metabolites are further metabolized into conjugates, which are then excreted in urine and feces. </p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ea5fbad3-ded0-e98d-77b4-30c3bb6168a1"></a><a name="section-3.2.4"></a><p></p>
<h3>Elimination </h3>
<p class="First">Following oral administration of an 80 mg dose of <span class="Sup">14</span>C-isotretinoin as a liquid suspension, <span class="Sup">14</span>C-activity in blood declined with a half-life of 90 hours. The metabolites of isotretinoin and any conjugates are ultimately excreted in the feces and urine in relatively equal amounts (total of 65% to 83%). After a single 80 mg oral dose of ZenataneÂ™ to 74 healthy adult subjects under fed conditions, the mean Â± SD elimination half-lives (t<span class="Sub">1/2</span>) of isotretinoin and 4-<span class="Italics">oxo</span>-isotretinoin were 21.0 Â± 8.2 hours and 24.0 Â± 5.3 hours, respectively. After both single and multiple doses, the observed accumulation ratios of isotretinoin ranged from 0.9 to 5.43 in patients with <span class="product-label-link" type="condition" conceptid="4028013" conceptname="Cystic acne">cystic acne</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="_0188efd2-813c-2f4d-7eee-193999efcbda"></a><a name="section-3.3"></a><p></p>
<h2><span class="Bold">Special Patient Populations</span></h2>
<p class="First">Pediatric Patients </p>
<p>The pharmacokinetics of isotretinoin were evaluated after single and multiple doses in 38 pediatric patients (12 to 15 years) and 19 adult patients (â‰¥18 years) who received ZenataneÂ™ for the treatment of severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. In both age groups, 4-oxo-isotretinoin was the major metabolite; tretinoin and 4-oxo-tretinoin were also observed. The dose-normalized pharmacokinetic parameters for isotretinoin following single and multiple doses are summarized in <span class="Bold">Table 3 </span>for pediatric patients. There were no statistically significant differences in the pharmacokinetics of isotretinoin between pediatric and adult patients.</p>
<p><span class="Bold">Table 3. Pharmacokinetic Parameters of Isotretinoin Following Single and Multiple Dose Administration in Pediatric Patients, 12 to 15 Years of Age </span><span class="Bold">Mean (</span>Â± <span class="Bold">SD), N=38*</span></p>
<a name="i5b091c26-32a1-4779-8440-00c4a567547d"></a><table border="1" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td><span class="Bold">Parameter</span></td>
<td>
<span class="Bold">Isotretinoin</span><span class="Bold">(Single Dose)</span>
</td>
<td>
<span class="Bold">Isotretinoin</span><span class="Bold">(Steady-State)</span>
</td>
</tr>
<tr>
<td>C<span class="Sub">max</span> (ng/mL)</td>
<td>573.25 (278.79)</td>
<td>731.98 (361.86)</td>
</tr>
<tr>
<td>AUC<span class="Sub">(0-12)</span> (ngâ‹…hr/mL)</td>
<td>3033.37 (1394.17)Â </td>
<td>5082 (2184.23)Â </td>
</tr>
<tr>
<td>AUC<span class="Sub">(0-24) </span>(ngâ‹…hr/mL)</td>
<td>6003.81 (2885.67)</td>
<td>â€“</td>
</tr>
<tr>
<td>T<span class="Sub">max </span>(hr)â€ </td>
<td>6(1 to 24.6)</td>
<td>4 (0 to12)</td>
</tr>
<tr>
<td>C<span class="Sub">ss</span>min (ng/mL)</td>
<td>â€“</td>
<td>352.32 (184.44)</td>
</tr>
<tr>
<td>T<span class="Sub">1/2</span> (hr)</td>
<td>â€“</td>
<td>15.69 (5.12)</td>
</tr>
<tr class="Last">
<td>CL/F (L/hr)</td>
<td>â€“</td>
<td>17.96 (6.27)</td>
</tr>
</tbody></table>
<p>*The single and multiple dose data in this table were obtained following a non-standardized meal that is not comparable to the high-fat meal that was used in the study in <span class="Bold">Table 2</span>. </p>
<p>â€ Median (range)</p>
<p>In pediatric patients (12 to 15 years), the mean Â± SD elimination half-lives (t<span class="Sub">1/2</span>) of isotretinoin and 4-oxo-isotretinoin were 15.7 Â± 5.1 hours and 23.1 Â± 5.7 hours, respectively. The accumulation ratios of isotretinoin ranged from 0.46 to 3.65 for pediatric patients.</p>
<p><span class="Bold"></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_5b3e9cfc-b807-3959-e1a9-ecf09ba84a41"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">Severe Recalcitrant Nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> </span></p>
<p><span class="Bold"></span>ZenataneÂ™ is indicated for the treatment of severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">Nodules</span> are inflammatory lesions with a diameter of 5 mm or greater. The <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> may become suppurative or hemorrhagic. â€œSevere,â€? by definition,<span class="Sup">2 </span>means â€œmanyâ€? as opposed to â€œfew or severalâ€? <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>. <span class="Underline">Because of significant adverse effects associated with its use, ZenataneÂ™ should be reserved for patients with severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> who are unresponsive to conventional therapy, including systemic antibiotics.</span> In addition, ZenataneÂ™ is indicated only for those female patients who are not pregnant, because ZenataneÂ™ can cause severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> (see <span class="Bold"><a href="#CONTRAINDICATIONS">BOXED </a><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a> AND <a href="#WARNINGS">WARNING</a>S</span>).Â </p>
<p>A single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients.<span class="Sup">1,3,4 </span>If a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off ZenataneÂ™. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth (see <span class="Bold"><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">WARNINGS: Skeletal: Bone Mineral Density, <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">Hyperostosis</span>, and <span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">Premature Epiphyseal Closure</span></a></span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">Pregnancy: Category X. See BOXED CONTRAINDICATIONS AND WARNINGS. </span></p>
<p><span class="Bold"></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> </span></p>
<p><span class="Bold"></span>ZenataneÂ™ is contraindicated in patients who are hypersensitive to this medication or to any of its components. Isotretinoin should not be given to patients who are sensitive to parabens, which are used as preservatives in the gelatin capsule (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></span>).</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_ccac1d3c-0bc9-721d-7c83-ac67d5a39b0c"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">Psychiatric Disorders</span></h2>
<p class="First"><span class="Bold">ZenataneÂ™ ay cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> and, rarely, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, and aggressive and/or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">violent behaviors</span>. No mechanism of action has been established for these events (see ADVERSE REACTIONS: Psychiatric). Prescribers should read the brochure, </span><span class="Bold Italics">Recognizing Psychiatric Disorders in Adolescents and Young Adults: A Guide for Prescribers of Isotretinoin.</span><span class="Bold">Prescribers should be alert to the warning signs of psychiatric disorders to guide patients to receive the help they need. Therefore, prior to initiation of ZenataneÂ™ therapy, patients and family members should be asked about any history of psychiatric disorder, and at each visit during therapy patients should be assessed for symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood disturbance, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> to determine if further evaluation may be necessary. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, as described in the brochure (â€œRecognizing Psychiatric Disorders in Adolescents and Young Adultsâ€?), include sad mood, hopelessness, feelings of guilt, worthlessness or helplessness, loss of pleasure or interest in activities, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, difficulty concentrating, change in sleep pattern, change in weight or appetite, suicidal thoughts or attempts, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, acting on dangerous impulses, and persistent physical symptoms unresponsive to treatment. Patients should stop ZenataneÂ™ and the patient or a family member should promptly contact their prescriber if the patient develops <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood disturbance, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, without waiting until the next visit. Discontinuation of ZenataneÂ™ therapy may be insufficient; further evaluation may be necessary. While such monitoring may be helpful, it may not detect all patients at risk. Patients may report mental health problems or family history of psychiatric disorders. These reports should be discussed with the patient and/or the patientâ€™s family. A referral to a mental health professional may be necessary. The physician should consider whether ZenataneÂ™ is appropriate in this setting; for some patients the risks may outweigh the benefits of ZenataneÂ™ therapy.</span></p>
<p><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_c9d7619d-00f5-7d11-85a5-891853850230"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor Cerebri</span></span></h2>
<p class="First"><span class="Bold">ZenataneÂ™ use has been associated with a number of cases of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span>), some of which involved concomitant use of tetracyclines. Concomitant treatment with tetracyclines should therefore be avoided. Early signs and symptoms of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> include <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. Patients with these symptoms should be screened for <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> and, if present, they should be told to discontinue ZenataneÂ™ immediately and be referred to a neurologist for further diagnosis and care (see <a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVERSE REACTIONS: Neurological</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_a095741e-d5e1-26ce-34d2-0bd10dbc0af8"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> </span></h2>
<p class="First">There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> and severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> [eg, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS), <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN)] associated with isotretinoin use. These events may be serious and result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, life-threatening events, hospitalization, or <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. Patients should be monitored closely for severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, and discontinuation of ZenataneÂ™ should be considered if warranted. </p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_21ded358-7b19-a038-6525-798664e3d40a"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> </span></h2>
<p class="First"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span> </span>has been reported in patients with either elevated or normal serum triglyceride levels. <span class="Bold">In rare instances, fatal <span class="product-label-link" type="condition" conceptid="4185268" conceptname="Acute hemorrhagic pancreatitis">hemorrhagic pancreatitis</span> has been reported. </span>ZenataneÂ™ should be stopped if <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> cannot be controlled at an acceptable level or if symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_9aad2a6b-eae4-e658-9206-d92cf6d5bd8c"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold">Lipids </span></h2>
<p class="First">Elevations of serum triglycerides in excess of 800 mg/dL have been reported in patients treated with ZenataneÂ™. Marked elevations of serum triglycerides were reported in approximately 25% of patients receiving ZenataneÂ™ in clinical trials. In addition, approximately 15% developed a decrease in high-density lipoproteins and about 7% showed an increase in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. In clinical trials, the effects on triglycerides, HDL, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> were reversible upon cessation of ZenataneÂ™ therapy. Some patients have been able to reverse triglyceride elevation by reduction in weight, restriction of dietary fat and alcohol, and reduction in dose while continuing ZenataneÂ™ <span class="Sup">5</span>. 
      </p>
<p>Blood lipid determinations should be performed before ZenataneÂ™ is given and then at intervals until the lipid response to ZenataneÂ™ is established, which usually occurs within 4 weeks. Especially careful consideration must be given to risk/benefit for patients who may be at high risk during ZenataneÂ™ therapy (patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, increased alcohol intake, <span class="product-label-link" type="condition" conceptid="437530" conceptname="Disorder of lipid metabolism">lipid metabolism disorder</span> or familial history of <span class="product-label-link" type="condition" conceptid="437530" conceptname="Disorder of lipid metabolism">lipid metabolism disorder</span>). If ZenataneÂ™ therapy is instituted, more frequent checks of serum values for lipids and/or blood sugar are recommended (see <span class="Bold"><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">PRECAUTIONS</a>: <a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Laboratory</a><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Tests</a></span>). </p>
<p>The cardiovascular consequences of <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> associated with ZenataneÂ™ are unknown. </p>
<p>Animal Studies: In rats given 8 or 32 mg/kg/day of isotretinoin (1.3 to 5.3 times the recommended clinical dose of 1.0 mg/kg/day after normalization for total body surface area) for 18 months or longer, the incidences of focal calcification, <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the myocardium, calcification of coronary, pulmonary and mesenteric arteries, and metastatic calcification of the gastric mucosa were greater than in control rats of similar age. Focal endocardial and myocardial calcifications associated with calcification of the coronary arteries were observed in two dogs after approximately 6 to 7 months of treatment with isotretinoin at a dosage of 60 to 120 mg/kg/day (30 to 60 times the recommended clinical dose of 1.0 mg/kg/day, respectively, after normalization for total body surface area).<span class="Sup"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_d25a09a9-7fdb-6a99-2215-5a4498f88439"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold">Hearing Impairment </span></h2>
<p class="First">Impaired hearing has been reported in patients taking ZenataneÂ™; in some cases, the hearing impairment has been reported to persist after therapy has been discontinued. Mechanism(s) and causality for this event have not been established. Patients who experience <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> or hearing impairment should discontinue ZenataneÂ™ treatment and be referred for specialized care for further evaluation (see <span class="Bold"><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVERSE</a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">REACTIONS</a>: <a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">Special</a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">Senses</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_c7a5b28d-201b-fa16-4f78-b8aa81d6e545"></a><a name="section-6.7"></a><p></p>
<h2><span class="Bold">Hepatotoxicity </span></h2>
<p class="First">Clinical <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> considered to be possibly or probably related to ZenataneÂ™ therapy has been reported. Additionally, mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials, some of which normalized with dosage reduction or continued administration of the drug. If normalization does not readily occur or if <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> is suspected during treatment with ZenataneÂ™, the drug should be discontinued and the etiology further investigated.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_cf48a472-7d22-3439-ddc3-5a642dbf9bd3"></a><a name="section-6.8"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span> </span></h2>
<p class="First">ZenataneÂ™ has been associated with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (including regional <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span>) in patients without a prior history of intestinal disorders. In some instances, symptoms have been reported to persist after ZenataneÂ™ treatment has been stopped. Patients experiencing <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> or severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> should discontinue ZenataneÂ™ immediately (see <span class="Bold"><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVERSE</a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">REACTIONS</a>: <a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">Gastrointestinal</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_625ac4c6-270b-54b0-1207-f75e124cfd0f"></a><a name="section-6.9"></a><p></p>
<h2><span class="Bold">Skeletal </span></h2>
<p class="First">Bone Mineral Density </p>
<p>Effects of multiple courses of ZenataneÂ™ on the developing musculoskeletal system are unknown. There is some evidence that long-term, high-dose, or multiple courses of therapy with isotretinoin have more of an effect than a single course of therapy on the musculoskeletal system. In an open-label clinical trial (N=217) of a single course of therapy with ZenataneÂ™ for severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, bone density measurements at several skeletal sites were not significantly decreased (lumbar spine change &gt;-4% and total hip change &gt;-5%) or were increased in the majority of patients. One patient had a decrease in lumbar spine bone mineral density &gt;4% based on unadjusted data. Sixteen (7.9%) patients had decreases in lumbar spine bone mineral density &gt;4%, and all the other patients (92%) did not have significant decreases or had increases (adjusted for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index). Nine patients (4.5%) had a decrease in total hip bone mineral density &gt;5% based on unadjusted data. Twenty-one (10.6%) patients had decreases in total hip bone mineral density &gt;5%, and all the other patients (89%) did not have significant decreases or had increases (adjusted for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index). Follow-up studies performed in eight of the patients with decreased bone mineral density for up to 11 months thereafter demonstrated increasing bone density in five patients at the lumbar spine, while the other three patients had lumbar spine bone density measurements below baseline values. Total hip bone mineral densities remained below baseline (range â€“1.6% to â€“7.6%) in five of eight patients (62.5%).</p>
<p>In a separate open-label extension study of ten patients, ages 13-18 years, who started a second course of ZenataneÂ™ four months after the first course, two patients showed a decrease in mean lumbar spine bone mineral density up to 3.25% (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS: Pediatric Use</a></span>). </p>
<p>Spontaneous reports of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>, bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, and delayed healing of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> have been seen in the ZenataneÂ™ population. While causality to ZenataneÂ™ has not been established, an effect cannot be ruled out. Longer term effects have not been studied. It is important that ZenataneÂ™ be given at the recommended doses for no longer than the recommended duration. </p>
<p><span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">Hyperostosis</span> </p>
<p>A high prevalence of skeletal <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span> was noted in clinical trials for disorders of keratinization with a mean dose of 2.24 mg/kg/day. Additionally, skeletal <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span> was noted in 6 of 8 patients in a prospective study of disorders of keratinization.<span class="Sup">6 </span>Minimal skeletal <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span> and calcification of ligaments and tendons have also been observed by x-ray in prospective studies of nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with a single course of therapy at recommended doses. The skeletal effects of multiple ZenataneÂ™ treatment courses for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> are unknown. </p>
<p>In a clinical study of 217 pediatric patients (12 to 17 years) with severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span> was not observed after 16 to 20 weeks of treatment with approximately 1 mg/kg/day of ZenataneÂ™ given in two divided doses. <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">Hyperostosis</span> may require a longer time frame to appear. The clinical course and significance remain unknown. </p>
<p><span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">Premature Epiphyseal Closure</span> </p>
<p>There are spontaneous reports of <span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">premature epiphyseal closure</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients receiving recommended doses of ZenataneÂ™. The effect of multiple courses of ZenataneÂ™ on epiphyseal closure is unknown. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_07ec5e9a-786a-876f-1c42-1c05fc8d6adb"></a><a name="section-6.10"></a><p></p>
<h2><span class="Bold">Vision Impairment </span></h2>
<p class="First">Visual problems should be carefully monitored. All ZenataneÂ™ patients experiencing visual difficulties should discontinue ZenataneÂ™ treatment and have an ophthalmological examination (see <span class="Bold"><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVAERSE </a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">REACTIONS: Special Senses</a></span>). </p>
<p>Corneal Opacities </p>
<p>Corneal opacities have occurred in patients receiving ZenataneÂ™ for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> and more frequently when higher drug dosages were used in patients with disorders of keratinization. The corneal opacities that have been observed in clinical trial patients treated with ZenataneÂ™ have either completely resolved or were resolving at follow-up 6 to 7 weeks after discontinuation of the drug (see <span class="Bold"><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVERSE</a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">REACTIONS: Special Senses</a></span>). </p>
<p><span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">Decreased Night Vision</span> </p>
<p><span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">Decreased night vision</span> has been reported during ZenataneÂ™ therapy and in some instances the event has persisted after therapy was discontinued. Because the onset in some patients was sudden, patients should be advised of this potential problem and warned to be cautious when driving or operating any vehicle at night.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">ZenataneÂ™ must only be prescribed by prescribers who are registered and activated with the iPLEDGE program. ZenataneÂ™ must only be dispensed by a pharmacy registered and activated with iPLEDGE, and must only be dispensed to patients who are registered and meet all the requirements of iPLEDGE. Registered and activated pharmacies must receive ZenataneÂ™ only from wholesalers registered with iPLEDGE. </p>
<p>iPLEDGE program requirements for wholesalers, prescribers, and pharmacists are described below: </p>
<p><span class="Bold">Wholesalers: </span></p>
<p>For the purpose of the iPLEDGE program, the term wholesaler refers to wholesaler, distributor, and/or chain pharmacy distributor. To distribute ZenataneÂ™, wholesalers must be registered with iPLEDGE, and agree to meet all iPLEDGE requirements for wholesale distribution of isotretinoin products. Wholesalers must register with iPLEDGE by signing and returning the iPLEDGE wholesaler agreement that affirms they will comply with all iPLEDGE requirements for distribution of isotretinoin. These include: </p>
<ul>
<li>Registering prior to distributing isotretinoin and re-registering annually thereafter </li>
<li>Distributing only FDA approved isotretinoin product</li>
<li>Only shipping isotretinoin to<span class="Bold"></span>
</li>
</ul>
<p> -wholesalers registered in the iPLEDGE program with prior written consent from the manufacturer or</p>
<p>-pharmacies licensed in the US and registered and activated in the iPLEDGE program</p>
<ul>
<li>Notifying the isotretinoin manufacturer (or delegate) of any non-registered and/or nonactivated pharmacy or unregistered wholesaler that attempts to order isotretinoin </li>
<li>Complying with inspection of wholesaler records for verification of compliance with the iPLEDGE program by the isotretinoin manufacturer (or delegate) </li>
<li>Returning to the manufacturer (or delegate) any undistributed product if registration is revoked by the manufacturer or if the wholesaler chooses to not re-register annually </li>
</ul>
<p><span class="Bold">Prescribers: </span></p>
<p>To prescribe isotretinoin, the prescriber must be registered and activated with the pregnancy risk management program iPLEDGE. Prescribers can register by signing and returning the completed registration form. Prescribers can only activate their registration by affirming that they meet requirements and will comply with all iPLEDGE requirements by attesting to the following points: </p>
<ul>
<li>I know the risk and severity of fetal injury/<span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> from isotretinoin.Â </li>
<li>I know the risk factors for unplanned pregnancy and the effective measures for avoidance of unplanned pregnancy. </li>
<li>I have the expertise to provide the patient with detailed pregnancy prevention counseling or I will refer her to an expert for such counseling, reimbursed by the manufacturer. </li>
<li>I will comply with the iPLEDGE program requirements described in the booklets entitled <span class="Italics">The Guide to Best Practices for the iPLEDGE Program </span>and <span class="Italics">The iPLEDGE Program Prescriber Contraception Counseling Guide. </span>
</li>
<li>Before beginning treatment of female patients of childbearing potential with isotretinoin and on a monthly basis, the patient will be counseled to avoid pregnancy by using two forms of contraception simultaneously and continuously one month before, during, and one month after isotretinoin therapy, unless the patient commits to continuous abstinence. </li>
<li>I will not prescribe isotretinoin to any female patient of childbearing potential until verifying she has a negative screening pregnancy test and monthly negative CLIA-certified (Clinical Laboratory Improvement Amendment) pregnancy tests. Patients should have a pregnancy test at the completion of the entire course of isotretinoin and another pregnancy test one month later. </li>
<li>I will report any pregnancy case that I become aware of while the female patient is on isotretinoin or one month after the last dose to the pregnancy registry.<span class="Bold"></span>
</li>
</ul>
<p>To prescribe isotretinoin, the prescriber must access the iPLEDGE system via the internet (www.ipledgeprogram.com) or telephone (1-866-495-0654) to:</p>
<p>1) Register each patient in the iPLEDGE program. </p>
<p>2) Confirm monthly that each patient has received counseling and education. </p>
<p>3) For female patients of childbearing potential: </p>
<ul>
<li>Enter patientâ€™s two chosen forms of contraception each month. </li>
<li>Enter monthly result from CLIA-certified laboratory conducted pregnancy test. </li>
</ul>
<p>Isotretinoin must only be prescribed to female patients who are known not to be pregnant as confirmed by a negative CLIA-certified laboratory conducted pregnancy test. </p>
<p>Isotretinoin must only be dispensed by a pharmacy registered and activated with the pregnancy risk management program iPLEDGE and only when the registered patient meets all the requirements of the iPLEDGE program. Meeting the requirements for a female patient of childbearing potential signifies that she: </p>
<ul>
<li>
<span class="Underline">Has</span> been counseled and has signed a Patient Information/Informed Consent About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> (for female patients who can get pregnant) form that contains warnings about the risk of potential <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> if the fetus is exposed to isotretinoin. The patient must sign the informed consent form before starting treatment and patient counseling must also be done at that time and on a monthly basis thereafter. </li>
<li>
<span class="Underline">Has</span> had two negative urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial isotretinoin prescription. The first test (a screening test) is obtained by the prescriber when the decision is made to pursue qualification of the patient for isotretinoin. The second pregnancy test (a confirmation test) must be done in a CLIA-certified laboratory. The interval between the two tests should be at least 19 days. </li>
</ul>
<p>-For patients with regular menstrual cycles, the second pregnancy test should be done during the first 5 days of the menstrual period immediately preceding the beginning of isotretinoin therapy and after the patient has used two forms of contraception for one month. </p>
<p>-For patients with <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, irregular cycles, or using a contraceptive method that precludes <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span>, the second pregnancy test must be done immediately preceding the beginning of isotretinoin therapy and after the patient has used two forms of contraception for one month. </p>
<ul>
<li>
<span class="Underline">Has had </span>a negative result from a urine or serum pregnancy test in a CLIA-certified laboratory before receiving each subsequent course of isotretinoin. A pregnancy test must be repeated every month, in a CLIA-certified laboratory, prior to the female patient receiving each prescription. </li>
<li>
<span class="Underline">Has</span> selected and has committed to use 2 forms of effective contraception simultaneously, at least 1 of which must be a primary form, unless the patient commits to continuous abstinence from heterosexual contact, or the patient has undergone a hysterectomy or bilateral oophorectomy, or has been medically confirmed to be post-menopausal. Patients must use 2 forms of effective contraception for at least 1 month prior to initiation of isotretinoin therapy, during isotretinoin therapy, and for 1 month after discontinuing isotretinoin therapy. Counseling about contraception and behaviors associated with an increased risk of pregnancy must be repeated on a monthly basis. </li>
</ul>
<p>If the patient has unprotected heterosexual intercourse at any time 1 month before, during, or 1 month after therapy, she must: </p>
<p>1. Stop taking ZenataneÂ™ immediately, if on therapy</p>
<p>2. Have a pregnancy test at least 19 days after the last act of unprotected heterosexual intercourse </p>
<p>3. Start using 2 forms of effective contraception simultaneously again for 1 month before resuming ZenataneÂ™ therapy </p>
<p>4. Have a second pregnancy test after using 2 forms of effective contraception for 1 month as described above depending on whether she has regular menses or not. </p>
<p>Effective forms of contraception include both primary and secondary forms of contraception:</p>
<a name="id20a86cb-003e-48f9-8ff7-4da3132d452e"></a><table border="1" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td colspan="1" rowspan="1" valign="top"><span class="Bold">Primary forms Â </span></td>
<td valign="top">Seconday forms</td>
</tr>
<tr>
<td valign="top">tubal sterilization</td>
<td valign="top">Barrier:</td>
</tr>
<tr>
<td valign="top">partnerâ€™s vasectomy</td>
<td valign="top">male latex condom with or without spermicide</td>
</tr>
<tr>
<td valign="top">intrauterine device Â Â Â Â Â Â Â  </td>
<td valign="top">diaphragm with spermicide </td>
</tr>
<tr>
<td valign="top">hormonal (combinationÂ oral contraceptives,transdermal patch,injectables, implantables, or vaginal ring) </td>
<td valign="top">cervical cap with spermicide Â </td>
</tr>
<tr class="Last">
<td valign="top">Â </td>
<td valign="top">Other:vaginal sponge (contains spermicide) </td>
</tr>
</tbody></table>
<p>Any birth control method can fail. There have been reports of pregnancy from female patients who have used oral contraceptives, as well as transdermal patch/injectable/implantable/vaginal ring hormonal birth control products; these pregnancies occurred while these patients were taking ZenataneÂ™. These reports are more frequent for female patients who use only a single method of contraception. Therefore, it is critically important that female patients of childbearing potential use two effective forms of contraception simultaneously. Patients must receive written warnings about the rates of possible contraception failure (included in patient education kits). </p>
<p>Using two forms of contraception simultaneously substantially reduces the chances that a female will become pregnant over the risk of pregnancy with either form alone. A drug interaction that decreases effectiveness of hormonal contraceptives has not been entirely ruled out for ZenataneÂ™ (see <span class="Bold"><a href="#_8a3bcf60-5206-1bbc-e96d-3e7b9aa9c3a0">PRECAUTIONS</a><a href="#_8a3bcf60-5206-1bbc-e96d-3e7b9aa9c3a0">: Drug Interactions</a></span>). Although hormonal contraceptives are highly effective, prescribers are advised to consult the package insert of any medication administered concomitantly with hormonal contraceptives, since some medications may decrease the effectiveness of these birth control products. </p>
<p>Patients should be prospectively cautioned not to self-medicate with the herbal supplement St. Johnâ€™s Wort because a possible interaction has been suggested with hormonal contraceptives based on reports of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on oral contraceptives shortly after starting St. Johnâ€™s Wort. Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. Johnâ€™s Wort. </p>
<p>If a pregnancy does occur during ZenataneÂ™ treatment, ZenataneÂ™ must be discontinued immediately. The patient should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling. Any suspected fetal exposure during or one month after ZenataneÂ™ therapy must be reported immediately to the FDA via the MedWatch number 1-800-FDA-1088 and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet (<a href="http://www.ipledgeprogram.com/">www.ipledgeprogram.com</a>).</p>
<p>All Patients</p>
<p>Isotretinoin is contraindicated in female patients who are pregnant. To receive isotretinoin all patients must meet all of the following conditions: </p>
<ul>
<li>
<span class="Underline">Must</span> be registered with the iPLEDGE program by the prescriber </li>
<li>
<span class="Underline">Must</span> understand that severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> can occur with the use of isotretinoin by female patients </li>
<li>
<span class="Underline">Must </span>be reliable in understanding and carrying out instructions </li>
<li>
<span class="Underline">Must</span> sign a Patient Information/Informed Consent (for all patients) form that contains warnings about the potential risks associated with isotretinoin </li>
<li>
<span class="Underline">Must</span> fill and pick up the prescription within 7 days of the date of specimen collection for the pregnancy test for female patients of childbearing potential </li>
<li>
<span class="Underline">Must</span> fill and pick up the prescription within 30 days of the office visit for male patients and female patients not of childbearing potential </li>
<li>
<span class="Underline">Must</span> not donate blood while on isotretinoin and for 1 month after treatment has ended </li>
<li>
<span class="Underline">Must</span> not share isotretinoin with anyone, even someone who has similar symptoms</li>
</ul>
<p>Female Patients of Childbearing Potential Isotretinoin is contraindicated in female patients who are pregnant. In addition to the requirements for all patients described above, female patients of childbearing potential must meet the following conditions:</p>
<ul>
<li>
<span class="Underline">Must </span>NOT be pregnant or breast-feeding</li>
<li>
<span class="Underline">Must</span> comply with the required pregnancy testing at a CLIA-certified laboratory </li>
<li>
<span class="Underline">Must</span> fill and pick up the prescription within 7 days of the date of specimen collection for the pregnancy test </li>
<li>
<span class="Underline">Must</span> be capable of complying with the mandatory contraceptive measures required for isotretinoin therapy, or commit to continuous abstinence from heterosexual intercourse, and understand behaviors associated with an increased risk of pregnancy </li>
<li>
<span class="Underline">Must</span> understand that it is her responsibility to avoid pregnancy one month before, during and one month after isotretinoin therapy </li>
<li>
<span class="Underline">Must</span> have signed an additional Patient Information/Informed Consent About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> (for female patients who can get pregnant) form, before starting isotretinoin, that contains warnings about the risk of potential <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> if the fetus is exposed to isotretinoin </li>
<li>
<span class="Underline">Must</span> access the iPLEDGE system via the internet (www.ipledgeprogram.com) or telephone (1-866-495-0654), before starting isotretinoin, on a monthly basis during therapy, and 1 month after the last dose to answer questions on the program requirements and to enter the patientâ€™s two chosen forms of contraception </li>
<li>
<span class="Underline">Must</span> have been informed of the purpose and importance of providing information to the iPLEDGE program should she become pregnant while taking isotretinoin or within one month of the last dose </li>
</ul>
<p><span class="Bold">Pharmacists: </span></p>
<p>To dispense isotretinoin, pharmacies must be registered and activated with the pregnancy risk management program iPLEDGE.</p>
<p>The Responsible Site Pharmacist must register the pharmacy by signing and returning the completed registration form. After registration, the Responsible Site Pharmacist can only activate the pharmacy registration by affirming that they meet requirements and will comply with all iPLEDGE requirements by attesting to the following points: </p>
<ul>
<li>I know the risk and severity of fetal injury/<span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> from isotretinoin.</li>
<li>I will train all pharmacists, who participate in the filling and dispensing of isotretinoin prescriptions, on the iPLEDGE program requirements. </li>
<li>I will comply and seek to ensure all pharmacists who participate in the filling and dispensing of isotretinoin prescriptions comply with the iPLEDGE program requirements described in the booklet entitled <span class="Italics">Pharmacist Guide for the iPLEDGE Program.</span>
</li>
<li>I will obtain ZenataneÂ™ product only from iPLEDGE registered wholesalers. </li>
<li>I will not sell, buy, borrow, loan or otherwise transfer isotretinoin in any manner to or from another pharmacy. </li>
<li>I will return to the manufacturer (or delegate) any unused product if registration is revoked by the manufacturer or if the pharmacy chooses to not reactivate annually. </li>
<li>I will not fill isotretinoin for any party other than a qualified patient. <span class="Bold"></span>
</li>
</ul>
<p>To dispense isotretinoin, the pharmacist must: </p>
<p>1) be trained by the Responsible Site Pharmacist concerning the iPLEDGE program requirements. </p>
<p>2) obtain authorization from the iPLEDGE program via the internet (www.ipledgeprogram.com) or telephone (1-866-495-0654) for every isotretinoin prescription. Authorization signifies that the patient has met all program requirements and is qualified to receive ZenataneÂ™. </p>
<p>3) write the Risk Management Authorization (RMA) number on the prescription.<br></p>
<p>ZenataneÂ™ must only be dispensed: </p>
<ul>
<li>in no more than a 30-day supply </li>
<li>with an ZenataneÂ™ Medication Guide </li>
<li>after authorization from the iPLEDGE program </li>
<li>prior to the â€œdo not dispense to patient afterâ€? date provided by the iPLEDGE system (within 30 days of the office visit for male patients and female patients not of child bearing potential and within 7 days of the date of specimen collection for female patients of child bearing potential) </li>
<li>with a new prescription for refills and another authorization from the iPLEDGE program (No automatic refills are allowed) </li>
</ul>
<p>An ZenataneÂ™ Medication Guide must be given to the patient each time ZenataneÂ™ is dispensed, as required by law. This ZenataneÂ™ Medication Guide is an important part of the risk management program for the patients. </p>
<p>ZenataneÂ™ must not be prescribed, dispensed or otherwise obtained through the internet or any other means outside of the iPLEDGE program. Only FDA-approved ZenataneÂ™ products must be distributed, prescribed, dispensed, and used. Patients must fill ZenataneÂ™ prescriptions only at U.S. licensed pharmacies. </p>
<p>A description of the iPLEDGE program educational materials available with iPLEDGE is provided below. The main goal of these educational materials is to explain the iPLEDGE program requirements and to reinforce the educational messages. </p>
<p>1) <span class="Italics">The Guide to Best Practices for the iPLEDGE Program includes:</span> isotretinoin teratogenic potential, information on pregnancy testing, and the method to complete a qualified ZenataneÂ™ prescription. </p>
<p>2) <span class="Italics">The iPLEDGE Program Prescriber Contraception Counseling Guide includes: </span>specific information about effective contraception, the limitations of contraceptive methods, behaviors associated with an increased risk of contraceptive failure and pregnancy and the methods to evaluate pregnancy risk. </p>
<p>3) <span class="Italics">The Pharmacist Guide for the iPLEDGE Program includes:</span> isotretinoin teratogenic potential and the method to obtain authorization to dispense an isotretinoin prescription. </p>
<p>4) The iPLEDGE program is a systematic approach to comprehensive patient education about their responsibilities and includes education for contraception compliance and reinforcement of educational messages. The iPLEDGE program includes information on the risks and benefits of ZenataneÂ™ which is linked to the Medication Guide dispensed by pharmacists with each isotretinoin prescription. </p>
<p>5) Female patients not of childbearing potential and male patients, and female patients of childbearing potential are provided with separate booklets. Each booklet contains information on isotretinoin therapy including precautions and warnings, a Patient Information/Informed Consent (for all patients) form, and a toll-free line which provides isotretinoin information in two languages. </p>
<p>6) The booklet for female patients not of childbearing potential and male patients, <span class="Italics">The iPLEDGE Program Guide to Isotretinoin for Male Patients and Female Patients Who Cannot Get Pregnant,</span> also includes information about male reproduction and a warning not to share ZenataneÂ™ with others or to donate blood during isotretinoin therapy and for 1 month following discontinuation of isotretinoin. </p>
<p>7) The booklet for female patients of childbearing potential, <span class="Italics">The iPLEDGE Program Guide to Isotretinoin for Female Patients Who Can Get Pregnant,</span> includes a referral program that offers female patients free contraception counseling, reimbursed by the manufacturer, by a reproductive specialist; and a second Patient Information/Informed Consent About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> (for female patients who can get pregnant) form concerning <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. </p>
<p>8) The booklet, <span class="Italics">The iPLEDGE Program Birth Control Workbook</span> includes information on the types of contraceptive methods, the selection and use of appropriate, effective contraception, the rates of possible contraceptive failure and a toll-free contraception counseling line. </p>
<p>9) In addition, there is a patient educational DVD with the following videos â€” â€œBe Prepared, Be Protectedâ€? and â€œBe Aware: The Risk of Pregnancy While on isotretinoinâ€? (see <span class="Bold"><a href="#PRECAUTIONS">Information</a><a href="#PRECAUTIONS">for Patients</a></span>).</p>
<p></p>
<div class="Section" data-sectionCode="34072-9">
<a name="_caf5c8a7-169b-98b5-db1e-7b284af448cb"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Although an effect of ZenataneÂ™ on bone loss is not established, physicians should use caution when prescribing ZenataneÂ™ to patients with a genetic predisposition for age-related <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, a history of childhood <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> conditions, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, or other disorders of bone metabolism. This would include patients diagnosed with <span class="product-label-link" type="condition" conceptid="436675" conceptname="Anorexia nervosa">anorexia nervosa</span> and those who are on chronic drug therapy that causes drug-induced <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>/<span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> and/or affects vitamin D metabolism, such as systemic corticosteroids and any anticonvulsant. </p>
<p>Patients may be at increased risk when participating in sports with repetitive impact where the risks of <span class="product-label-link" type="condition" conceptid="4167097" conceptname="Spondylolisthesis">spondylolisthesis</span> with and without pars <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> and hip growth plate injuries in early and late adolescence are known. There are spontaneous reports of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> and/or delayed healing in patients while on therapy with ZenataneÂ™ or following cessation of therapy with isotretinoin while involved in these activities. While causality to ZenataneÂ™ has not been established, an effect must not be ruled out. </p>
<p><span class="Bold">Information for Patients </span></p>
<p>See <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS </a></span>and <span class="Bold"><a href="#BOXED_WARNING">Boxed</a><a href="#BOXED_WARNING">CONTRAINDICATIONS</a><a href="#BOXED_WARNING">AND WARNINGS</a></span>. </p>
<ul>
<li>Patients must be instructed to read the Medication Guide supplied as required by law when ZenataneÂ™ is dispensed. The complete text of the Medication Guide is reprinted at the end of this document. For additional information, patients must also be instructed to read the iPLEDGE program patient educational materials. All patients must sign the Patient Information/Informed Consent (for all patients) form. </li>
<li>Female patients of childbearing potential must be instructed that they must not be pregnant when ZenataneÂ™ therapy is initiated, and that they should use 2 forms of effective contraception simultaneously for 1 month before starting ZenataneÂ™, while taking ZenataneÂ™, and for 1 month after ZenataneÂ™ has been stopped, unless they commit to continuous abstinence from heterosexual intercourse. They should also sign a second Patient Information/Informed Consent About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> (for female patients who can get pregnant) form prior to beginning ZenataneÂ™ therapy. They should be given an opportunity to view the patient DVD provided by the manufacturer to the prescriber. The DVD includes information about contraception, the most common reasons that contraception fails, and the importance of using 2 forms of effective contraception when taking teratogenic drugs and comprehensive information about types of potential <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> which could occur if a female patient who is pregnant takes ZenataneÂ™ at any time during pregnancy. Female patients should be seen by their prescribers monthly and have a urine or serum pregnancy test, in a CLIA-certified laboratory, performed each month during treatment to confirm negative pregnancy status before another ZenataneÂ™ prescription is written (see <span class="Bold"><a href="#BOXED_WARNING">Boxed</a><a href="#BOXED_WARNING">CONTRAINDICATIONS</a><a href="#BOXED_WARNING">AND</a><a href="#BOXED_WARNING">WARNINGS</a></span>and <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>). </li>
<li>ZenataneÂ™ is found in the semen of male patients taking ZenataneÂ™, but the amount delivered to a female partner would be about 1 million times lower than an oral dose of 40 mg. While the no-effect limit for isotretinoin induced embryopathy is unknown, 20 years of post-marketing reports include 4 with isolated defects compatible with features of retinoid exposed fetuses; however 2 of these reports were incomplete, and two had other possible explanations for the defects observed.</li>
<li>Prescribers should be alert to the warning signs of psychiatric disorders to guide patients to receive the help they need. Therefore, prior to initiation of ZenataneÂ™ treatment, patients and family members should be asked about any history of psychiatric disorder, and at each visit during treatment patients should be assessed for symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood disturbance, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> to determine if further evaluation may be necessary. <span class="Bold">Signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> include sad mood, hopelessness, feelings of guilt, worthlessness or helplessness, loss of pleasure or interest in activities, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, difficulty concentrating, change in sleep pattern, change in weight or appetite, suicidal thoughts or attempts, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, acting on dangerous impulses, and persistent physical symptoms unresponsive to treatment</span>. Patients should stop ZenataneÂ™ and the patient or a family member should promptly contact their prescriber if the patient develops <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood disturbance, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, without waiting until the next visit. Discontinuation of ZenataneÂ™ treatment may be insufficient; further evaluation may be necessary. While such monitoring may be helpful, it may not detect all patients at risk. Patients may report mental health problems or family history of psychiatric disorders. These reports should be discussed with the patient and/or the patientâ€™s family. A referral to a mental health professional may be necessary. The physician should consider whether ZenataneÂ™ therapy is appropriate in this setting; for some patients the risks may outweigh the benefits of ZenataneÂ™ therapy.</li>
<li>Patients must be informed that some patients, while taking ZenataneÂ™ or soon after stopping ZenataneÂ™, have become depressed or developed other serious mental problems. Symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> include sad, â€œanxiousâ€? or empty mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, acting on dangerous impulses, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, loss of pleasure or interest in social or sports activities, sleeping too much or too little, changes in weight or appetite, school or work performance going down, or trouble concentrating. Some patients taking ZenataneÂ™ have had thoughts about hurting themselves or putting an end to their own lives (suicidal thoughts). Some people tried to end their own lives. And some people have ended their own lives. There were reports that some of these people did not appear depressed. There have been reports of patients on ZenataneÂ™ becoming aggressive or violent. No one knows if ZenataneÂ™ caused these behaviors or if they would have happened even if the person did not take ZenataneÂ™. Some people have had other signs of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> while taking ZenataneÂ™. </li>
<li>Patients must be informed that they must not share ZenataneÂ™ with anyone else because of the risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and other serious adverse events. </li>
<li>Patients must be informed not to donate blood during therapy and for one month following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to ZenataneÂ™. </li>
<li>Patients should be reminded to take ZenataneÂ™ with a meal (see <span class="Bold"><a href="#_2702a7c7-239a-ff77-7cdc-18982b805c7d">DOSAGE</a></span><span class="Bold"><a href="#_2702a7c7-239a-ff77-7cdc-18982b805c7d">AND ADMINISTRATION</a></span>). To decrease the risk of esophageal irritation, patients should swallow the capsules with a full glass of liquid. </li>
<li>Patients should be informed that transient exacerbation (flare) of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> has been seen, generally during the initial period of therapy. </li>
<li>Wax epilation and skin resurfacing procedures (such as dermabrasion, laser) should be avoided during ZenataneÂ™ therapy and for at least 6 months thereafter due to the possibility of <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span> (see <span class="Bold"><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVERSE</a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">REACTIONS</a>: <a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">Skin</a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561"> and Appendages</a></span>). </li>
<li>Patients should be advised to avoid prolonged exposure to UV rays or sunlight. </li>
<li>Patients should be informed that they may experience decreased tolerance to contact lenses during and after therapy. </li>
<li>Patients should be informed that approximately 16% of patients treated with ZenataneÂ™ in a clinical trial developed musculoskeletal symptoms (including <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>) during treatment. In general, these symptoms were mild to moderate, but occasionally required discontinuation of the drug. Transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest has been reported less frequently. In the clinical trial, these symptoms generally cleared rapidly after discontinuation of ZenataneÂ™, but in some cases persisted (see <span class="Bold"><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVERSE REACTIONS: </a><a href="#PRECAUTIONS">Musculoskeletal</a></span>). There have been rare post marketing reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, some associated with strenuous physical activity (see <span class="Bold"><a href="#_2c495a29-f28a-ab6f-f919-0d9daa9c5312">Laboratory</a><a href="#_2c495a29-f28a-ab6f-f919-0d9daa9c5312">Tests</a>: <a href="#_2c495a29-f28a-ab6f-f919-0d9daa9c5312">CPK</a></span>). </li>
<li>Pediatric patients and their caregivers should be informed that approximately 29% (104/358) of pediatric patients treated with ZenataneÂ™ developed <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>. <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> was severe in 13.5% (14/104) of the cases and occurred at a higher frequency in female patients than male patients. <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span> were experienced in 22% (79/358) of pediatric patients. <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span> were severe in 7.6% (6/79) of patients. Appropriate evaluation of the musculoskeletal system should be done in patients who present with these symptoms during or after a course of ZenataneÂ™. Consideration should be given to discontinuation of ZenataneÂ™ if any significant abnormality is found. </li>
<li><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and rare cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported. ZenataneÂ™ should be discontinued if clinically significant decreases in white cell counts occur. </li>
<li>Patients should be advised that severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) have been reported in post-marketing data. ZenataneÂ™ should be discontinued if clinically significant <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> occur. <span class="Bold"></span>
</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported. Cutaneous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and serious cases of <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">allergic vasculitis</span>, often with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> (<span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> and red patches) of the extremities and extracutaneous involvement (including renal) have been reported. Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> necessitates discontinuation of therapy and appropriate medical management. </p>
<p></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="_8a3bcf60-5206-1bbc-e96d-3e7b9aa9c3a0"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions </h2>
<p class="First">Drug Interactions </p>
<ul>
<li>
<span class="Italics">Vitamin A:</span> Because of the relationship of ZenataneÂ™ to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects. </li>
<li>
<span class="Italics">Tetracyclines:</span> Concomitant treatment with ZenataneÂ™ and tetracyclines should be avoided because ZenataneÂ™ use has been associated with a number of cases of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span>), some of which involved concomitant use of tetracyclines.</li>
<li>
<span class="Italics">Micro-dosed Progesterone Preparations:</span> Micro-dosed progesterone preparations (â€œminipillsâ€? that do not contain an estrogen) may be an inadequate method of contraception during ZenataneÂ™ therapy. Although other hormonal contraceptives are highly effective, there have been reports of pregnancy from female patients who have used combined oral contraceptives, as well as transdermal patch/injectable/implantable/vaginal ring hormonal birth control products. These reports are more frequent for female patients who use only a single method of contraception. It is not known if hormonal contraceptives differ in their effectiveness when used with ZenataneÂ™. Therefore, it is critically important for female patients of childbearing potential to select and commit to use two forms of effective contraception simultaneously, at least one of which must be a primary form (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>).</li>
<li>
<span class="Italics">Norethindrone/ethinyl estradiol:</span> In a study of 31 premenopausal female patients with severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> receiving OrthoNovum<span class="Sup">Â®</span> 7/7/7 Tablets as an oral contraceptive agent, ZenataneÂ™ at the recommended dose of 1 mg/kg/day, did not induce clinically relevant changes in the pharmacokinetics of ethinyl estradiol and norethindrone and in the serum levels of progesterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Prescribers are advised to consult the package insert of medication administered concomitantly with hormonal contraceptives, since some medications may decrease the effectiveness of these birth control products.</li>
<li>
<span class="Italics">St. Johnâ€™s Wort:</span><span class="Bold">ZenataneÂ™</span><span class="Bold"></span><span class="Bold">use is associated with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in some patients</span>Â (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a>:</span> Psychiatric Disorders and <span class="Bold"><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVERSE </a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">REACTIONS</a></span>: Psychiatric). Patients should be prospectively cautioned not to self-medicate with the herbal supplement St. Johnâ€™s Wort because a possible interaction has been suggested with hormonal contraceptives based on reports of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on oral contraceptives shortly after starting St. John's Wort. Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. John's Wort.</li>
<li>
<span class="Italics">Phenytoin:</span> ZenataneÂ™ has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers. These results are consistent with the in vitro finding that neither isotretinoin nor its metabolites induce or inhibit the activity of the CYP 2C9 human hepatic P450 enzyme. Phenytoin is known to cause <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>. No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between phenytoin and ZenataneÂ™. Therefore, caution should be exercised when using these drugs together.</li>
<li>
<span class="Italics">Systemic Corticosteroids: </span>Systemic corticosteroids are known to cause <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between systemic corticosteroids and ZenataneÂ™. Therefore, caution should be exercised when using these drugs together. </li>
</ul>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="_eba51800-9ac3-e828-ba45-54e0d2d01de0"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<ul><li><span class="Italics">Pregnancy Test: </span></li></ul>
<p class="First">- Female patients of childbearing potential <span class="Underline">must</span> have had two negative urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial ZenataneÂ™ prescription. The first test (a screening test) is obtained by the prescriber when the decision is made to pursue qualification of the patient for ZenataneÂ™. The second pregnancy test (a confirmation test) must be done in a CLIA-certified laboratory. The interval between the two tests must be at least 19 days. </p>
<p>- For patients with regular menstrual cycles, the second pregnancy test must be done during the first 5 days of the menstrual period immediately preceding the beginning of ZenataneÂ™ therapy and after the patient has used 2 forms of contraception for 1 month. </p>
<p>- For patients with <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, irregular cycles, or using a contraceptive method that precludes <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span>, the second pregnancy test must be done immediately preceding the beginning of ZenataneÂ™ therapy and after the patient has used 2 forms of contraception for 1 month. </p>
<p>- Each month of therapy, patients must have a negative result from a urine or serum pregnancy test. A pregnancy test must be repeated each month, in a CLIA-certified laboratory, prior to the female patient receiving each prescription.</p>
<ul>
<li>
<span class="Italics">Lipids:</span> Pretreatment and follow-up blood lipids should be obtained under fasting conditions. After consumption of alcohol, at least 36 hours should elapse before these determinations are made. It is recommended that these tests be performed at weekly or biweekly intervals until the lipid response to ZenataneÂ™ is established. The incidence of <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> is one patient in four on ZenataneÂ™ therapy (see <span class="Bold"><a href="#_9aad2a6b-eae4-e658-9206-d92cf6d5bd8c">WARNINGS</a>: <a href="#_9aad2a6b-eae4-e658-9206-d92cf6d5bd8c">Lipids</a></span>). </li>
<li>
<span class="Italics">Liver Function Tests:</span> Since elevations of liver enzymes have been observed during clinical trials, and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> has been reported, pretreatment and follow-up liver function tests should be performed at weekly or biweekly intervals until the response to ZenataneÂ™ has been established (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a>: <a href="#_c7a5b28d-201b-fa16-4f78-b8aa81d6e545">Hepatotoxicity</a></span>). </li>
<li>
<span class="Italics">Glucose:</span> Some patients receiving ZenataneÂ™ have experienced problems in the control of their blood sugar. In addition, new cases of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been diagnosed during ZenataneÂ™ therapy, although no causal relationship has been established. </li>
<li>
<span class="Italics">CPK:</span> Some patients undergoing vigorous physical activity while on ZenataneÂ™ therapy have experienced elevated CPK levels; however, the clinical significance is unknown. There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, some associated with strenuous physical activity. In a clinical trial of 217 pediatric patients (12 to 17 years) with severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, transient elevations in CPK were observed in 12% of patients, including those undergoing strenuous physical activity in association with reported musculoskeletal adverse events such as <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="444130" conceptname="Injury of foot">limb injury</span>, or muscle <span class="product-label-link" type="condition" conceptid="30234" conceptname="Neck sprain">sprain</span>. In these patients, approximately half of the CPK elevations returned to normal within 2 weeks and half returned to normal within 4 weeks. No cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> were reported in this trial. </li>
</ul>
<p></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="_0a8b3cf7-e75a-2d40-e7f5-4be2cacda659"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenesis, Mutagenesis and Impairment of Fertility </p>
<p>In male and female Fischer 344 rats given oral isotretinoin at dosages of 8 or 32 mg/kg/day (1.3 to 5.3 times the recommended clinical dose of 1.0 mg/kg/day, respectively, after normalization for total body surface area) for greater than 18 months, there was a dose related increased incidence of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> relative to controls. The incidence of adrenal medullary <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was also increased at the higher dosage in both sexes. The relatively high level of spontaneous <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> occurring in the male Fischer 344 rat makes it an equivocal model for study of this tumor; therefore, the relevance of this tumor to the human population is uncertain. </p>
<p>The Ames test was conducted with isotretinoin in two laboratories. The results of the tests in one laboratory were negative while in the second laboratory a weakly positive response (less than 1.6 x background) was noted in <span class="Italics">S. typhimurium </span>TA100 when the assay was conducted with metabolic activation. No dose-response effect was seen and all other <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> were negative. Additionally, other tests designed to assess genotoxicity (Chinese hamster cell assay, mouse micronucleus test, <span class="Italics">S. cerevisiae</span> D7 assay, in vitro clastogenesis assay with human-derived <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and unscheduled DNA synthesis assay) were all negative. </p>
<p>In rats, no adverse effects on gonadal function, fertility, conception rate, gestation or parturition were observed at oral dosages of isotretinoin of 2, 8, or 32 mg/kg/day (0.3, 1.3, or 5.3 times the recommended clinical dose of 1.0 mg/kg/day, respectively, after normalization for total body surface area). </p>
<p>In dogs, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> was noted after treatment with oral isotretinoin for approximately 30 weeks at dosages of 20 or 60 mg/kg/day (10 or 30 times the recommended clinical dose of 1.0 mg/kg/day, respectively, after normalization for total body surface area). In general, there was microscopic evidence for appreciable <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of spermatogenesis but some sperm were observed in all testes examined and in no instance were completely atrophic tubules seen. In studies of 66 men, 30 of whom were patients with nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> under treatment with oral isotretinoin, no significant changes were noted in the count or motility of spermatozoa in the ejaculate. In a study of 50 men (ages 17 to 32 years) receiving isotretinoin therapy for nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, no significant effects were seen on ejaculate volume, sperm count, total sperm motility, morphology or seminal plasma fructose.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="_8a120ee0-42eb-e2fa-cdb2-2484e4a789fd"></a><a name="section-7.5"></a><p></p>
<h2>
<span class="Bold">Pregnancy: Category X.</span><span class="Bold"> See </span><span class="Bold">BOXED CONTRAINDICATIONS AND WARNINGS.</span><span class="Bold"></span>
</h2>
<p class="First"></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="_d36a13af-9088-f6ff-0f38-c46387e2e44f"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because of the potential for adverse effects, nursing mothers should not receive ZenataneÂ™. </p>
<p></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="_8db8ee95-9f85-d607-842e-12c53a20ae0e"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The use of ZenataneÂ™ in pediatric patients less than 12 years of age has not been studied. The use of ZenataneÂ™ for the treatment of severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> in pediatric patients ages 12 to 17 years should be given careful consideration, especially for those patients where a known metabolic or structural bone disease exists (see <span class="Bold"><a href="#_caf5c8a7-169b-98b5-db1e-7b284af448cb">PRECAUTIONS</a>: <a href="#_caf5c8a7-169b-98b5-db1e-7b284af448cb">General</a></span>). Use of ZenataneÂ™ in this age group for severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> is supported by evidence from a clinical study comparing 103 pediatric patients (13 to 17 years) to 197 adult patients (â‰¥18 years). Results from this study demonstrated that ZenataneÂ™, at a dose of 1 mg/kg/day given in two divided doses, was equally effective in treating severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> in both pediatric and adult patients.</p>
<p>In studies with ZenataneÂ™, adverse reactions reported in pediatric patients were similar to those described in adults except for the increased incidence of <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (both of which were sometimes severe) and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> in pediatric patients (see <span class="Bold"><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVERSE</a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">REACTIONS</a></span>). </p>
<p>In an open-label clinical trial (N=217) of a single course of therapy with ZenataneÂ™ for severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, bone density measurements at several skeletal sites were not significantly decreased (lumbar spine change &gt;-4% and total hip change &gt;-5%) or were increased in the majority of patients. One patient had a decrease in lumbar spine bone mineral density &gt;4% based on unadjusted data. Sixteen (7.9%) patients had decreases in lumbar spine bone mineral density &gt;4%, and all the other patients (92%) did not have significant decreases or had increases (adjusted for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index). Nine patients (4.5%) had a decrease in total hip bone mineral density &gt;5% based on unadjusted data. Twenty-one (10.6%) patients had decreases in total hip bone mineral density &gt;5%, and all the other patients (89%) did not have significant decreases or had increases (adjusted for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index). Follow-up studies performed in eight of the patients with decreased bone mineral density for up to 11 months thereafter demonstrated increasing bone density in five patients at the lumbar spine, while the other three patients had lumbar spine bone density measurements below baseline values. Total hip bone mineral densities remained below baseline (range âˆ’1.6% to âˆ’7.6%) in 5 of 8 patients (62.5%). </p>
<p>In a separate open-label extension study of ten patients, ages 13 to 18 years, who started a second course of ZenataneÂ™ 4 months after the first course, two patients showed a decrease in mean lumbar spine bone mineral density up to 3.25% (see <span class="Bold"><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">WARNINGS</a>: <a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Skeletal</a>: <a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Bone Mineral Density</a></span>). </p>
<p></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="_b21e6aa8-125c-8959-f8bf-73e9e40ff696"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of isotretinoin did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Although reported clinical experience has not identified differences in responses between elderly and younger patients, effects of aging might be expected to increase some risks associated with isotretinoin therapy (see <span class="Bold"><a href="#WARNINGS">WARNINGS </a></span>and <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>).</p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_01bfe988-86b3-eace-2de8-41c1acc4a6de"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold">Clinical Trials and Post-marketing Surveillance </span></h2>
<p class="First">The adverse reactions listed below reflect the experience from investigational studies of ZenataneÂ™, and the post-marketing experience. The relationship of some of these events to ZenataneÂ™ therapy is unknown. Many of the side effects and adverse reactions seen in patients receiving ZenataneÂ™ are similar to those described in patients taking very high doses of vitamin A (dryness of the skin and mucous membranes, e.g., of the lips, nasal passage, and eyes). </p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_0eaee1fa-5fa0-b624-3590-a93e01bd0835"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold">Dose Relationship </span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">Cheilitis</span> and <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> are usually dose related. Most adverse reactions reported in clinical trials were reversible when therapy was discontinued; however, some persisted after cessation of therapy (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>and <span class="Bold"><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">ADVERSE </a><a href="#_6a5f1bef-3313-5e78-f4e9-cbae2e0e5561">REACTIONS</a></span>). </p>
<p>Body as a Whole </p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></span>), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> </p>
<p>Cardiovascular </p>
<p><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, vascular thrombotic disease, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></p>
<p>Endocrine/Metabolic </p>
<p><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (see <span class="Bold"><a href="#_9aad2a6b-eae4-e658-9206-d92cf6d5bd8c">WARNINGS</a>: <a href="#_9aad2a6b-eae4-e658-9206-d92cf6d5bd8c">Lipids</a></span>), alterations in blood sugar levels (see <span class="Bold"><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">PRECAUTIONS</a>: <a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Laboratory</a><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Tests</a></span>)</p>
<p>Gastrointestinal </p>
<p><span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (see <span class="Bold"><a href="#_cf48a472-7d22-3439-ddc3-5a642dbf9bd3">WARNINGS</a>: <a href="#_cf48a472-7d22-3439-ddc3-5a642dbf9bd3">Inflammatory</a><a href="#_cf48a472-7d22-3439-ddc3-5a642dbf9bd3">Bowel</a><a href="#_cf48a472-7d22-3439-ddc3-5a642dbf9bd3">Disease</a></span>), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (see <span class="Bold"><a href="#_c7a5b28d-201b-fa16-4f78-b8aa81d6e545">WARNINGS</a>: <a href="#_c7a5b28d-201b-fa16-4f78-b8aa81d6e545">Hepatotoxicity</a></span>), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (see <span class="Bold"><a href="#_9aad2a6b-eae4-e658-9206-d92cf6d5bd8c">WARNINGS</a>: <a href="#_9aad2a6b-eae4-e658-9206-d92cf6d5bd8c">Lipids</a></span>), <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the gums, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>/<span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span>, <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, other nonspecific <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> </p>
<p>Hematologic </p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></span>), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, rare reports of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS">Information </a><a href="#PRECAUTIONS">for</a><a href="#PRECAUTIONS">Patients</a></span>). See <span class="Bold"><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">PRECAUTIONS</a>:<a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0"> Laboratory Tests </a></span>for other hematological parameters.</p>
<p>Musculoskeletal </p>
<p>skeletal <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span>, calcification of tendons and ligaments, <span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">premature epiphyseal closure</span>, decreases in bone mineral density (see <span class="Bold"><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">WARNINGS</a>: <a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Skeletal</a></span>), musculoskeletal symptoms (sometimes severe) including <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS">Information </a><a href="#PRECAUTIONS">for</a><a href="#PRECAUTIONS"></a><a href="#PRECAUTIONS">Patients</a></span>), transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS">Information </a><a href="#PRECAUTIONS">for</a><a href="#PRECAUTIONS"></a><a href="#PRECAUTIONS">Patients</a></span>), <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span>, other types of bone abnormalities, elevations of CPK/rare reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (see <span class="Bold"><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">PRECAUTIONS</a>: <a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Laboratory</a><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Tests</a></span>).  </p>
<p>Neurological </p>
<p><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (see <span class="Bold"><a href="#_c9d7619d-00f5-7d11-85a5-891853850230">WARNINGS</a>: <a href="#_c9d7619d-00f5-7d11-85a5-891853850230"><span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Pseudotumor</span></a><a href="#_c9d7619d-00f5-7d11-85a5-891853850230">Cerebri</a></span>), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p>
<p>Psychiatric </p>
<p><span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">violent behaviors</span> (see <span class="Bold"><a href="#_ccac1d3c-0bc9-721d-7c83-ac67d5a39b0c">WARNINGS</a>: <a href="#_ccac1d3c-0bc9-721d-7c83-ac67d5a39b0c">Psychiatric</a><a href="#_ccac1d3c-0bc9-721d-7c83-ac67d5a39b0c">Disorders</a></span>), <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> </p>
<p>Of the patients reporting <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, some reported that the <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> subsided with discontinuation of therapy and recurred with reinstitution of therapy. </p>
<p>Reproductive System </p>
<p>abnormal menses  </p>
<p>Respiratory </p>
<p><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasms</span> (with or without a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>), <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span></p>
<p>Skin and Appendages </p>
<p><span class="product-label-link" type="condition" conceptid="4263196" conceptname="Acne fulminans">acne fulminans</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> (which in some cases persists), <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">cheilitis</span> (<span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">dry lips</span>), <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">dry nose</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4033043" conceptname="Eruptive xanthoma">eruptive xanthomas</span>,<span class="Sup">7 </span><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, fragility of skin, hair abnormalities, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, hyperpigmentation and hypopigmentation, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (including disseminated herpes simplex), <span class="product-label-link" type="condition" conceptid="4336254" conceptname="Dystrophia unguium">nail dystrophy</span>, <span class="product-label-link" type="condition" conceptid="137057" conceptname="Paronychia">paronychia</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of palms and soles, photoallergic/photosensitizing reactions, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4308074" conceptname="Pyogenic granuloma">pyogenic granuloma</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, and <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, sunburn susceptibility increased, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> (including Wegenerâ€™s granulomatosis; see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></span>), abnormal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing (delayed healing or exuberant granulation tissue with crusting; see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS">Information </a><a href="#PRECAUTIONS">for</a><a href="#PRECAUTIONS">Patients</a></span>)</p>
<p>Special Senses </p>
<p><span class="Italics">Hearing </span></p>
<p><span class="Italics"></span>hearing impairment (see <span class="Bold"><a href="#_d25a09a9-7fdb-6a99-2215-5a4498f88439">WARNINGS</a>: <a href="#_d25a09a9-7fdb-6a99-2215-5a4498f88439">Hearing</a><a href="#_d25a09a9-7fdb-6a99-2215-5a4498f88439">Impairment</a></span>), <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Italics">Vision </span></p>
<p>corneal opacities (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a>: <a href="#WARNINGS">Corneal</a><a href="#WARNINGS">Opacities</a></span>), <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">decreased night vision</span> which may persist (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a>: <a href="#WARNINGS">Decreased</a><a href="#WARNINGS">Night</a><a href="#WARNINGS">Vision</a></span>), <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, color vision disorder, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, eyelid <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> </p>
<p>Urinary System </p>
<p><span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span> (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></span>), nonspecific urogenital findings (see <span class="Bold"><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">PRECAUTIONS</a>: <a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Laboratory</a><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Tests</a></span>for other urological parameters) <span class="Italics"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2c495a29-f28a-ab6f-f919-0d9daa9c5312"></a><a name="section-8.3"></a><p></p>
<h2><span class="Bold">Laboratory </span></h2>
<p class="First">Elevation of plasma triglycerides (see <span class="Bold"><a href="#_9aad2a6b-eae4-e658-9206-d92cf6d5bd8c">WARNINGS</a>: <a href="#_9aad2a6b-eae4-e658-9206-d92cf6d5bd8c">Lipids</a></span>), decrease in serum high-density lipoprotein (HDL) levels, elevations of serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> during treatment </p>
<p>Increased alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST), SGPT (ALT), GGTP or LDH (see <span class="Bold"><a href="#_c7a5b28d-201b-fa16-4f78-b8aa81d6e545">WARNINGS</a>: <a href="#_c7a5b28d-201b-fa16-4f78-b8aa81d6e545">Hepatotoxicity</a></span>) </p>
<p>Elevation of fasting blood sugar, elevations of CPK (see <span class="Bold"><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">PRECAUTIONS</a>: <a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Laboratory</a><a href="#_eba51800-9ac3-e828-ba45-54e0d2d01de0">Tests</a></span>), <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> </p>
<p>Decreases in red blood cell parameters, decreases in white blood cell counts (including severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and rare reports of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS">Information</a><a href="#PRECAUTIONS">for</a><a href="#PRECAUTIONS">Patients</a></span>), <span class="product-label-link" type="condition" conceptid="4013526" conceptname="ESR raised">elevated sedimentation rates</span>, elevated platelet counts, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> </p>
<p>White cells in the urine, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, microscopic or gross <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="_184b05d4-0bb2-5d8e-629c-5dd532745298"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The oral LD<span class="Sub">50 </span>of isotretinoin is greater than 4000 mg/kg in rats and mice (&gt;600 times the recommended clinical dose of 1.0 mg/kg/day after normalization of the rat dose for total body surface area and &gt;300 times the recommended clinical dose of 1.0 mg/kg/day after normalization of the mouse dose for total body surface area) and is approximately 1960 mg/kg in rabbits (653 times the recommended clinical dose of 1.0 mg/kg/day after normalization for total body surface area). In humans, overdosage has been associated with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">cheilosis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. These symptoms quickly resolve without apparent residual effects. </p>
<p>ZenataneÂ™ causes serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> at any dosage (see <span class="Bold"><a href="#BOXED_WARNING">Boxed</a><a href="#BOXED_WARNING">CONTRAINDICATIONS </a></span>AND<span class="Bold"><a href="#BOXED_WARNING">WARNINGS</a></span>). Female patients of childbearing potential who present with isotretinoin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> must be evaluated for pregnancy. Patients who are pregnant should receive counseling about the risks to the fetus, as described in the <span class="Bold"><a href="#BOXED_WARNING">Boxed</a><a href="#BOXED_WARNING">CONTRAINDICATIONS </a></span>AND<span class="Bold"><a href="#BOXED_WARNING">WARNINGS</a></span><span class="Bold"></span>. Non-pregnant patients must be warned to avoid pregnancy for at least one month and receive contraceptive counseling as described in <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>. Educational materials for such patients can be obtained by calling the manufacturer. Because an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> would be expected to result in higher levels of isotretinoin in semen than found during a normal treatment course, male patients should use a condom, or avoid reproductive sexual activity with a female patient who is or might become pregnant, for one month after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. All patients with isotretinoin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should not donate blood for at least one month. </p>
<p></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_2702a7c7-239a-ff77-7cdc-18982b805c7d"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">ZenataneÂ™ should be administered with a meal (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a>: <a href="#PRECAUTIONS">Information</a><a href="#PRECAUTIONS">for </a><a href="#PRECAUTIONS">Patients</a></span>).</p>
<p>The recommended dosage range for ZenataneÂ™ is 0.5 to 1.0 mg/kg/day given in two divided doses with food for 15 to 20 weeks. In studies comparing 0.1, 0.5, and 1.0 mg/kg/day,<span class="Sup">8 </span>it was found that all dosages provided initial clearing of disease, but there was a greater need for retreatment with the lower dosages. During treatment, the dose may be adjusted according to response of the disease and/or the appearance of clinical side effects â€” some of which may be dose related. Adult patients whose disease is very severe with <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span> or is primarily manifested on the trunk may require dose adjustments up to 2.0 mg/kg/day, as tolerated. Failure to take ZenataneÂ™ with food will significantly decrease absorption. Before upward dose adjustments are made, the patients should be questioned about their compliance with food instructions. </p>
<p>The safety of once daily dosing with ZenataneÂ™ has not been established. Once daily dosing is <span class="Bold">not </span>recommended. </p>
<p>If the total <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodule</span> count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, the drug may be discontinued. After a period of 2 months or more off therapy, and if warranted by persistent or recurring severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, a second course of therapy may be initiated. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth. Long-term use of ZenataneÂ™, even in low doses, has not been studied, and is not recommended. It is important that ZenataneÂ™ be given at the recommended doses for no longer than the recommended duration. The effect of long-term use of ZenataneÂ™ on bone loss is unknown (see <span class="Bold"><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">WARNINGS</a>: <a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Skeletal</a>: <a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Bone</a><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Mineral </a><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Density</a></span>, <span class="Bold"><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f"><span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">Hyperostosis</span></a></span>, and <span class="Bold"><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Premature </a><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Epiphyseal </a><a href="#_625ac4c6-270b-54b0-1207-f75e124cfd0f">Closure</a></span>). </p>
<p>Contraceptive measures must be followed for any subsequent course of therapy (see <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>).</p>
<p><span class="Bold">Table 4 ZenataneÂ™ Dosing by Body Weight (Based on Administration With Food)</span></p>
<a name="ibe721604-4974-4846-8443-6ae31ef808b2"></a><table border="1" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td colspan="2" valign="top"><span class="Bold">Body Weight</span></td>
<td colspan="3" valign="top"><span class="Bold">Total mg/day</span></td>
</tr>
<tr>
<td valign="top"><span class="Bold">kilograms</span></td>
<td valign="top"><span class="Bold">pounds</span></td>
<td valign="top"><span class="Bold">0.5 mg/kg </span></td>
<td valign="top"><span class="Bold">1 mg/kg </span></td>
<td valign="top"><span class="Bold">2 mg/kg* </span></td>
</tr>
<tr>
<td valign="top">40</td>
<td valign="top">Â Â 88</td>
<td valign="top">20 </td>
<td valign="top">40 </td>
<td valign="top">Â  80 </td>
</tr>
<tr>
<td valign="top">50</td>
<td valign="top">110</td>
<td valign="top">25 </td>
<td valign="top">50 </td>
<td valign="top">100 </td>
</tr>
<tr>
<td valign="top">60</td>
<td valign="top">132</td>
<td valign="top">30 </td>
<td valign="top">60 </td>
<td valign="top">120 </td>
</tr>
<tr>
<td valign="top">70</td>
<td valign="top">154</td>
<td valign="top">35 </td>
<td valign="top">70 </td>
<td valign="top">140 </td>
</tr>
<tr>
<td valign="top">80</td>
<td valign="top">176</td>
<td valign="top">40 </td>
<td valign="top">80 </td>
<td valign="top">160 </td>
</tr>
<tr>
<td valign="top">90</td>
<td valign="top">198</td>
<td valign="top">45 </td>
<td valign="top">90 </td>
<td valign="top">180 </td>
</tr>
<tr class="Last">
<td valign="top">100</td>
<td valign="top">220</td>
<td valign="top">50 </td>
<td valign="top">100 </td>
<td valign="top">200 </td>
</tr>
</tbody></table>
<p>*See <span class="Bold">DOSAGE AND ADMINISTRATION</span>: the recommended dosage range is 0.5 to 1 mg/kg/day.</p>
<a name="iab1ec9e6-07b6-4dcc-89dc-4737dd43d77e"></a><table border="1" cellpadding="0" cellspacing="0"><tbody class="Headless"><tr class="First Last"><td valign="top">
<span class="Bold">INFORMATION FOR PHARMACISTS </span>Access the iPLEDGE system via the internet (www.ipledgeprogram.com) or telephone (1-866495-0654) to obtain an authorization and the <span class="Bold">â€œdo not dispense to patient afterâ€? </span>date. ZenataneÂ™ must only be dispensed in no more than a 30-day supply.</td></tr></tbody></table>
<a name="i1755d980-b40d-4e21-8baf-c743b1cf87d7"></a><table border="1" cellpadding="0" cellspacing="0"><tbody class="Headless"><tr class="First Last"><td valign="top">
<span class="Bold">REFILLS REQUIRE A NEW PRESCRIPTION AND A NEW AUTHORIZATION FROM THE iPLEDGE SYSTEM. </span>A ZenataneÂ™ medication guide must be given to the patient each time ZenataneÂ™ are dispensed, as required by law. This ZenataneÂ™ medication guide is an important part of the risk management program for the patient.</td></tr></tbody></table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="_97b606fd-131b-a4f6-e2bf-63ac44c04014"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ZenataneÂ™ (isotretinoin capsules USP) 10 mg are opaque blue elliptical soft gelatin capsules imprinted with black ink, â€œR135â€? on one side and are supplied in boxes of 30 containing 3 prescription packs of 10 capsules and in boxes of 100 containing 10 prescription packs of 10 capsules, as unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span></p>
<p>Boxes of 30 (3 Prescription Packs of 10 capsules)</p>
<p></p>
<p>ZenataneÂ™ (isotretinoin capsules USP) 20 mg are opaque pink elliptical soft gelatin capsules imprinted with black ink, â€œR136â€? on one side and are supplied in boxes of 30 containing 3 prescription packs of 10 capsules and in boxes of 100 containing 10 prescription packs of 10 capsules, as unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span></p>
<p>Boxes of 30 (3 Prescription Packs of 10 capsules)Â Â Â Â Â Â Â  NDC 54868-6425-0</p>
<p></p>
<p>ZenataneÂ™ (isotretinoin capsules USP) 40 mg are opaque green elliptical soft gelatin capsules imprinted with black ink, â€œR137â€? on one side and are supplied in boxes of 30 containing 3 prescription packs of 10 capsules and 100 containing 10 prescription packs of 10 capsules, as unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>.Â </p>
<p>Boxes of 30 (3 Prescription Packs of 10 capsules)Â Â Â Â Â  NDC 54868-6426-0</p>
<p></p>
<p><span class="Bold">Storage</span></p>
<p>Store at 68Â° to 77Â°F (20Â° to 25Â°C) [See USP Controlled Room Temperature]. Protect from light.<span class="Bold"></span></p>
<p><span class="Bold">REFERENCES</span></p>
<p>1. Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> with <span class="Italics">13-cis-retinoic acid. N Engl J Med</span> 300:329-333, 1979. </p>
<p>2. Pochi PE, Shalita AR, Strauss JS, Webster SB. Report of the consensus conference on <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> classification. J Am Acad Dermatol 24:495-500, 1991. </p>
<p>3. Farrell LN, Strauss JS, Stranieri AM. The treatment of severe <span class="product-label-link" type="condition" conceptid="4028013" conceptname="Cystic acne">cystic acne</span> with<span class="Italics"> 13-cis-retinoic acid: </span>evaluation of sebum production and the clinical response in a multiple-dose trial. J Am Acad Dermatol 3:602-611, 1980. </p>
<p>4. Jones H, Blanc D, Cunliffe WJ. <span class="Italics">13-cis-retinoic acid and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. Lancet</span> 2:1048-1049, 1980. </p>
<p>5. Katz RA, Jorgensen H, Nigra TP. Elevation of serum triglyceride levels from oral isotretinoin in disorders of keratinization. Arch Dermatol 116:1369-1372, 1980. </p>
<p>6. Ellis CN, Madison KC, Pennes DR, Martel W, Voorhees JJ. Isotretinoin therapy is associated with early skeletal radiographic changes. J Am Acad Dermatol 10:1024-1029, 1984. </p>
<p>7. Dicken CH, Connolly SM. <span class="product-label-link" type="condition" conceptid="4033043" conceptname="Eruptive xanthoma">Eruptive xanthomas</span> associated with isotretinoin <span class="Italics">(13-cis-retinoic acid). </span>Arch Dermatol 116:951-952, 1980. </p>
<p>8. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>: results of a multicenter dose-response study. J Am Acad Dermatol 10:490-496, 1984.</p>
<p></p>
<p>OrthoNovum 7/7/7 is a registered trademark of Ortho-McNeil Pharmaceutical, Inc.</p>
<p></p>
<p>Rx Only</p>
<p>Manufactured by:</p>
<p><span class="Bold">Cipla Limited</span></p>
<p><span class="Bold"></span>Kurkumbh Village</p>
<p>Pune â€“ 413 802 INDIA</p>
<p></p>
<p>Manufactured for:</p>
<p><span class="Bold">Dr. Reddyâ€™s Laboratories Limited</span></p>
<p><span class="Bold"></span>Bachupally â€“ 500 090 INDIAÂ </p>
<p>Issued: 0213<span class="Bold"></span></p>
<p><span class="Bold"></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First">Distributed by:</p>
<p>Physicians Total Care, Inc.</p>
<p>Tulsa, OKÂ  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="_e94b6e09-7358-05ca-a960-41dda70543c7"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">Patient Information</span></h1>
<p class="First"><span class="Bold">Patient Information/Informed Consent About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span></span><span class="Bold">(for female patients who can get pregnant)</span></p>
<p>To be completed by the patient (and her parent or guardian* if patient is under age 18) and signed by her doctor.</p>
<p>Read each item below and initial in the space provided to show that you understand each item and agree to follow your doctor's instructions. <span class="Bold">Do not sign this consent and do not take isotretinoin if there is anything that you do not understand. </span></p>
<p>*A parent or guardian of a minor patient (under age 18) must also read and initial each item before signing the consent.</p>
<p> _________________________________________________________</p>
<p>(Patientâ€™s Name)</p>
<p>1. I understand that there is a very high chance that my unborn baby could have severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> if I am pregnant or become pregnant while taking isotretinoin. This can happen with any amount and even if taken for short periods of time. This is why I must not be pregnant while taking isotretinoin. </p>
<p>Initial: ______ </p>
<p>2. I understand that I must not get pregnant one month before, during the entire time of my treatment, and for one month after the end of my treatment with isotretinoin. </p>
<p>Initial: ______ </p>
<p>3. I understand that I must avoid sexual intercourse completely, or I must use two separate, effective forms of birth control (contraception) <span class="Bold">at the same time</span>. The only exceptions are if I have had surgery to remove the uterus (a hysterectomy) or both of my ovaries (bilateral oophorectomy), or my doctor has medically confirmed that I am post-menopausal.</p>
<p>Initial: ______ </p>
<p>4. I understand that hormonal birth control products are among the most effective forms of birth control. Combination birth control pills and other hormonal products include skin patches, shots, under-the-skin implants, vaginal rings, and intrauterine devices (IUDs). Any form of birth control can fail. That is why I must use two different birth control methods at the same time, starting one month before, during, and for one month after stopping therapy every time I have sexual intercourse, even if one of the methods I choose is hormonal birth control. </p>
<p>Initial: ______</p>
<p>5. I understand that the following are effective forms of birth control: </p>
<a name="ic656e5fe-a4d7-404e-8c76-a0ec4a332bd6"></a><table border="1" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td>Primary forms</td>
<td>Secondary formsÂ </td>
</tr>
<tr>
<td>tubal sterilization (tying my tubes)</td>
<td>Barrier:</td>
</tr>
<tr>
<td>partnerâ€™s vasectomy</td>
<td>male latex condom with or without spermicide</td>
</tr>
<tr>
<td>intrauterine device</td>
<td>diaphragm with spermicide</td>
</tr>
<tr>
<td rowspan="3">hormonal (combination birth control pills, skin patches, shots, under- the-skin implants, or vaginal ring)Â </td>
<td>cervical cap with spermicide</td>
</tr>
<tr><td>Other: </td></tr>
<tr class="Last"><td>vaginal sponge (contains spermicide)</td></tr>
</tbody></table>
<p>A diaphragm and cervical cap must each be used with spermicide, a special cream that kills sperm</p>
<p>I understand that at least one of my two forms of birth control must be a primary method. </p>
<p>Initial: ______</p>
<p>6. I will talk with my doctor about any medicines including herbal products I plan to take during my isotretinoin treatment because hormonal birth control methods may not work if I am taking certain medicines or herbal products. </p>
<p>Initial: ______ </p>
<p>7. I may receive a free birth control counseling session from a doctor or other family planning expert. My isotretinoin doctor can give me an isotretinoin Patient Referral Form for this free consultation. </p>
<p>Initial: ______ </p>
<p>8. I must begin using the birth control methods I have chosen as described above at least one month before I start taking isotretinoin. </p>
<p>Initial: ______</p>
<p>9.I cannot get my first prescription for isotretinoin unless my doctor has told me that I have two <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> results. The first pregnancy test should be done when my doctor decides to prescribe isotretinoin. The second pregnancy test must be done in a lab during the first 5 days of my menstrual period right before starting isotretinoin therapy treatment or as instructed by my doctor. I will then have 1 pregnancy test; in a lab. </p>
<ul>
<li>every month during treatment </li>
<li>at the end of treatment </li>
<li>and 1 month after stopping treatment <span class="Bold"></span><span class="Bold"></span>
</li>
</ul>
<p>I must not start taking isotretinoin until I am sure that I am not pregnant, have negative results from two pregnancy tests, and the second test has been done in a lab. </p>
<p>Initial: ______</p>
<p>10. I have read and understand the materials my doctor has given to me, including <span class="Italics">The iPLEDGE Program Guide for Isotretinoin for Female Patients Who Can Get Pregnant, The iPLEDGE Birth Control Workbook</span> and <span class="Italics">The iPLEDGE Program Patient Introductory Brochure.</span></p>
<p>My doctor gave me and asked me to watch the DVD containing a video about birth control and a video about <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and isotretinoin. </p>
<p>I was told about a private counseling line that I may call for more information about birth control. I have received information on emergency birth control. </p>
<p>Initial: ______ </p>
<p>11. I must stop taking isotretinoin right away and call my doctor if I get pregnant, miss my expected menstrual period, stop using birth control or have sexual intercourse without using my two birth control methods at any time. Initial: ______ </p>
<p>12. My doctor gave me information about the purpose and importance of providing information to the iPLEDGE program should I become pregnant while taking isotretinoin or within one month of the last dose. I also understand that if I become pregnant, information about my pregnancy, my health, and my babyâ€™s health may be shared with the maker of isotretinoin and their authorized parties who maintain the iPLEDGE program and government health regulatory authorities. </p>
<p>Initial: ______ </p>
<p>13. I understand that being qualified to receive isotretinoin in the iPLEDGE program means that </p>
<p>I: </p>
<ul>
<li>have had 2 negative urine or blood pregnancy tests before receiving the first isotretinoin prescription. The second test must be done in a lab. I must have a negative result from a urine or blood pregnancy test done in a lab repeated each month before I receive another isotretinoin prescription.</li>
<li>have chosen and agreed to use 2 forms of effective birth control at the same time. At least 1 method must be a primary form of birth control, <span class="Bold">unless I have chosen never to have sexual contact with a male (abstinence)</span>, or I have undergone a hysterectomy. I must use 2 forms of birth control for at least 1 month before I start isotretinoin therapy, during therapy, and for 1 month after stopping therapy. I must receive counseling, repeated on a monthly basis, about birth control and behaviors associated with an increased risk of pregnancy. </li>
<li>have signed a Patient Information/Informed Consent About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> (for female patients who can get pregnant) that contains warnings about the chance of possible <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> if I am pregnant or become pregnant and my unborn baby is exposed to isotretinoin. </li>
<li>have been informed of and understand the purpose and importance of providing information to the iPLEDGE program should I become pregnant while taking isotretinoin or within one month of the last dose. </li>
<li>have interacted with the iPLEDGE program before starting isotretinoin and on a monthly basis to answer questions on the program requirements and to enter my two chosen forms of birth control.<span class="Italics"></span>
</li>
</ul>
<p>Initial: ______ </p>
<p><span class="Bold">My doctor has answered all my questions about isotretinoin and I understand that </span><span class="Bold Underline">it is my responsibility not to get pregnant 1 month before, during isotretinoin treatment, or for 1 month after I stop taking isotretinoin. </span></p>
<p>Initial: ______ </p>
<p>I now authorize my doctor ________________ to begin my treatment with isotretinoin. Patient Signature:_____________________________________ Date: ______ Parent/Guardian Signature (if under age 18):________________ Date:______ Please print: Patient Name and Address_______________________________ ______________________________ Telephone _______________________ </p>
<p>I have fully explained to the patient, __________________, the nature and purpose of the Â treatment described above and the risks to female patients of childbearing potential. I have asked the patient if she has any questions regarding her treatment with isotretinoin and have answered those questions to the best of my ability. </p>
<p>Doctor Signature: __________________________________ Date: ______ </p>
<p><span class="Bold">PLACE THE ORIGINAL SIGNED DOCUMENTS IN THE PATIENTâ€™S MEDICAL RECORD. Â PLEASE PROVIDE A COPY TO THE PATIENT.</span></p>
<p></p>
<p><span class="Bold">Patient Information/Informed Consent (for all patients):</span></p>
<p>To be completed by patient (and parent or guardian if patient is under age 18) and signed by the doctor. </p>
<p>Read each item below and initial in the space provided if you understand each item and agree to follow your doctorâ€™s instructions. A parent or guardian of a patient under age 18 must also read and understand each item before signing the agreement. </p>
<p><span class="Bold">Do not sign this agreement and do not take isotretinoin if there is anything that you do not understand about all the information you have received about using isotretinoin.</span></p>
<p>1. I, ______________________________________________________, </p>
<p>(Patientâ€™s Name) </p>
<p>understand that isotretinoin is a medicine used to treat severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> that cannot be cleared up by any other <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> treatments, including antibiotics. In severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, many red, swollen, tender lumps form in the skin. If untreated, severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>. </p>
<p>Initials: ______ </p>
<p>2. My doctor has told me about my choices for treating my <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. </p>
<p>Initials: ______ </p>
<p>3. I understand that there are serious side effects that may happen while I am taking isotretinoin. Â These have been explained to me. These side effects include serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in babies of pregnant patients. [Note: There is a second Patient Information/Informed Consent About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> (for female patients who can get pregnant)]. </p>
<p>Initials: ______ </p>
<p>4. I understand that some patients, while taking isotretinoin or soon after stopping isotretinoin, have become depressed or developed other serious mental problems. Symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> include sad, â€œanxiousâ€? or empty mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, acting on dangerous impulses, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, loss of pleasure or interest in social or sports activities, sleeping too much or too little, changes in weight or appetite, school or work performance going down, or trouble concentrating. Some patients taking isotretinoin have had thoughts about hurting themselves or putting an end to their own lives (suicidal thoughts). Some people tried to end their own lives. And some people have ended their own lives. There were reports that some of these people did not appear depressed. There have been reports of patients on isotretinoin becoming aggressive or violent. No one knows if isotretinoin caused these behaviors or if they would have happened even if the person did not take isotretinoin. Some people have had other signs of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> while taking isotretinoin (see #7 below). </p>
<p>Initials: ______</p>
<p>5. Before I start taking isotretinoin, I agree to tell my doctor if I have <span class="Bold">ever </span>had symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (see #7 below), been <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span>, had any other mental problems, or take medicine for any of these problems. Being <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> means having a loss of contact with reality, such as hearing voices or seeing things that are not there. </p>
<p>Initials: ______ </p>
<p>6. Before I start taking isotretinoin, I agree to tell my doctor if, to the best of my knowledge, anyone in my family has ever had symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, been <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span>, or had any other serious mental problems. </p>
<p>Initials: ______ </p>
<p>7. Once I start taking isotretinoin, I agree to stop using isotretinoin and tell my doctor right away if any of the following signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> happen. I: </p>
<ul>
<li>Start to feel sad or have <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span> spells </li>
<li>Lose interest in activities I once enjoyed </li>
<li>Sleep too much or have trouble sleeping</li>
<li> Become more <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span>, angry, or aggressive than usual (for example, temper outbursts, thoughts of violence) </li>
<li>Have a change in my appetite or body weight </li>
<li>Have trouble concentrating </li>
<li>Withdraw from my friends or family </li>
<li>Feel like I have no energy </li>
<li>Have feelings of worthlessness or guilt </li>
<li>Start having thoughts about hurting myself or taking my own life (suicidal thoughts) </li>
<li>Start acting on dangerous impulses </li>
<li>Start seeing or hearing things that are not real <span class="Bold"></span><span class="Bold"></span><span class="Bold"></span><span class="Bold Underline"></span>
</li>
</ul>
<p>Initials: ______ </p>
<p><span class="Bold">8. I agree to return to see my doctor every month I take isotretinoin to get a new prescription for isotretinoin, to check my progress and to check for signs of side effects. </span></p>
<p><span class="Bold"></span>Initials: ______ </p>
<p>9. Isotretinoin will be prescribed just for me â€” I will not share isotretinoin with other people because it may cause serious side effects, including <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. </p>
<p>Initials: ______ </p>
<p>10. I will not give blood while taking isotretinoin or for one month after I stop taking isotretinoin. I understand that if someone who is pregnant gets my donated blood, her baby may be exposed to isotretinoin and may be born with serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Â </p>
<p>Initials: ______</p>
<p>11. I have read The iPLEDGE Program Patient Introductory Brochure, and other materials my provider gave me containing important safety information about isotretinoin. I understand all the information I received. </p>
<p>Initials: ______ </p>
<p>12. My doctor and I have decided I should take isotretinoin. I understand that I must be qualified in the iPLEDGE program to have my prescription filled each month. I understand that I can stop taking isotretinoin at any time. I agree to tell my doctor if I stop taking isotretinoin. Â </p>
<p>Initials: ______</p>
<p>I now allow my doctor ___________________________ to begin my treatment with isotretinoin. </p>
<p><span class="Bold">Patient Signature: ____________________________________ Date: ______ </span></p>
<p><span class="Bold"></span>Parent/Guardian Signature (if under age 18): _______________ Date: ______ </p>
<p>Patient Name (print) ___________________________________</p>
<p> Patient Address ___________________________ Telephone (___.___.___) </p>
<p>___________________________________  </p>
<p>I have: </p>
<ul>
<li>fully explained to the patient, __________________, the nature and purpose of isotretinoin treatment, including its benefits and risks </li>
<li>given the patient the appropriate educational materials, The iPLEDGE Program Patient Introductory Brochure and asked the patient if he/she has any questions regarding his/her treatment with isotretinoin answered those questions to the best of my ability </li>
</ul>
<p>Doctor Signature: _________________________________ Date: ______</p>
<p><span class="Bold">PLACE THE ORIGINAL SIGNED DOCUMENTS IN THE PATIENTâ€™S MEDICAL RECORD. PLEASE PROVIDE A COPY TO THE PATIENT.</span><span class="Bold">Â </span></p>
<p></p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="_8ac856a9-40d0-d8bc-9079-8ae9a4535f70"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">MEDICATION GUIDE</span></h1>
<p class="First"><span class="Bold"><span class="Bold">ZENATANE<span class="Sup">TM</span> (</span><span class="Bold">ZEN â€“ a â€“ tÄ?n) <br></span><span class="Bold">(isotretinoin capsules)</span></span></p>
<p><span class="Bold"></span>Read the Medication Guide that comes with ZenataneÂ™ before you start taking it and each time you get a prescription. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.Â </p>
<p><span class="Bold">What is the most important information I should know about ZenataneÂ™? </span></p>
<ul>
<li>
<span class="Bold"></span>ZenataneÂ™  is used to treat a type of severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>) that has not been helped by other treatments, including antibiotics. </li>
<li>Because ZenataneÂ™ can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, ZenataneÂ™ is only for patients who can understand and agree to carry out all of the instructions in the iPLEDGE program. </li>
<li>ZenataneÂ™ may cause serious mental health problems. Â </li>
</ul>
<p><span class="Bold">1.Â  <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> (deformed babies), loss of a baby before birth (<span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>), <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the baby, and early (premature) births. </span>Female patients who are pregnant or who plan to become pregnant must not take ZenataneÂ™. <span class="Bold">Female patients must not get pregnant: </span></p>
<ul>
<li>
<span class="Bold"></span>for one month before starting ZenataneÂ™ </li>
<li>while taking ZenataneÂ™ </li>
<li>for one month after stopping ZenataneÂ™Â </li>
</ul>
<p><span class="Bold">If you get pregnant while taking ZenataneÂ™, stop taking it right away and call your doctor. </span>Doctors and patients should report all cases of pregnancy to: </p>
<ul>
<li>FDA MedWatch at 1-800-FDA-1088, and </li>
<li>the iPLEDGE pregnancy registry at 1-866-495-0654</li>
</ul>
<p><span class="Bold">2. Serious mental health problems. </span>ZenataneÂ™ may cause: </p>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </span></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> </span>(seeing or hearing things that are not real) </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></span>. Some patients taking ZenataneÂ™ have had thoughts about hurting themselves or putting an end to their own lives (suicidal thoughts). Some people tried to end their own lives. And some people have ended their own lives. Â </li>
</ul>
<p><span class="Bold">Stop ZenataneÂ™ and call your doctor right away if you or a family member notices that you have any of the following signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>: </span></p>
<ul>
<li>start to feel sad or have <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span> spells </li>
<li>lose interest in activities you once enjoyed </li>
<li>sleep too much or have trouble sleeping </li>
<li>become more <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span>, angry, or aggressive than usual (for example, temper outbursts, thoughts of violence) </li>
<li>have a change in your appetite or body weight </li>
<li>have trouble concentrating </li>
<li>withdraw from your friends or family </li>
<li>feel like you have no energy </li>
<li>have feelings of worthlessness or guilt </li>
<li>start having thoughts about hurting yourself or taking your own life (suicidal thoughts) </li>
<li>start acting on dangerous impulses start seeing or hearing things that are not real Â </li>
</ul>
<p>After stopping ZenataneÂ™, you may also need follow-up mental health care if you had any of these symptoms. </p>
<p><span class="Bold">What is ZenataneÂ™? </span></p>
<p><span class="Bold"></span>ZenataneÂ™ is a medicine taken by mouth to treat the most severe form of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>) that cannot be cleared up by any other <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> treatments, including antibiotics. ZenataneÂ™ can cause serious side effects (see <span class="Bold">â€œWhat is the most important information I should know about ZenataneÂ™?â€?</span>). ZenataneÂ™ can only be: </p>
<ul>
<li>prescribed by doctors that are registered in the iPLEDGE program </li>
<li>dispensed by a pharmacy that is registered with the iPLEDGE program </li>
<li>given to patients who are registered in the iPLEDGE program and agree to do everything required in the program</li>
</ul>
<p><span class="Bold">What is severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>? </span></p>
<p><span class="Bold"></span>Severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> is when many red, swollen, tender lumps form in the skin. These can be the size of pencil erasers or larger. If untreated, nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>. </p>
<p><span class="Bold">Who should not take ZenataneÂ™? </span></p>
<ul>
<li>
<span class="Bold"></span><span class="Bold"></span><span class="Bold">Do not take ZenataneÂ™ if you are pregnant, plan to become pregnant, or become pregnant during ZenataneÂ™ treatment. </span>ZenataneÂ™ causes severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. See <span class="Bold">â€œWhat is the most important information I should know about ZenataneÂ™?â€? </span>
</li>
<li>
<span class="Bold">Do not take ZenataneÂ™ if you are allergic to anything in it. </span>See the end of this Medication Guide for a complete list of ingredients in ZenataneÂ™.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking ZenataneÂ™? </span></p>
<p><span class="Bold"></span><span class="Bold">Tell your doctor if you or a family member has any of the following health conditions: </span></p>
<ul>
<li>
<span class="Bold"></span>mental problems </li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> </li>
<li>liver disease </li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> </li>
<li>heart disease </li>
<li>bone loss (<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>) or weak bones </li>
<li>an eating problem called <span class="product-label-link" type="condition" conceptid="436675" conceptname="Anorexia nervosa">anorexia nervosa</span> (where people eat too little) </li>
<li>food or medicine allergies Â </li>
</ul>
<p><span class="Bold">Tell your doctor if you are pregnant or breast-feeding. Zenatan</span>e<span class="Bold"> must not be used by women who are pregnant or breast feeding.</span><span class="Bold">Â </span></p>
<p><span class="Bold"></span><span class="Bold">Tell your doctor about all of the medicines you take including prescription and nonÂ­prescription medicines, vitamins and herbal supplements. </span>ZenataneÂ™ and certain other medicines can interact with each other, sometimes causing serious side effects. Especially tell your doctor if you take: </p>
<ul>
<li>
<span class="Bold">Vitamin A supplements. </span>Vitamin A in high doses has many of the same side effects as ZenataneÂ™. Taking both together may increase your chance of getting side effects. </li>
<li>
<span class="Bold">Tetracycline antibiotics. </span>Tetracycline antibiotics taken with ZenataneÂ™ can increase the chances of getting increased pressure in the brain. </li>
<li>
<span class="Bold">Progestin-only birth control pills (mini-pills). </span>They may not work while you take ZenataneÂ™. Ask your doctor or pharmacist if you are not sure what type you are using. </li>
<li>
<span class="Bold">Dilantin (phenytoin). </span>This medicine taken with ZenataneÂ™ may weaken your bones. </li>
<li>
<span class="Bold">Corticosteroid medicines. </span>These medicines taken with ZenataneÂ™ may weaken your bones. </li>
<li>
<span class="Bold">St. Johnâ€™s Wort. </span>This herbal supplement may make birth control pills work less effectively. Â </li>
</ul>
<p><span class="Bold">These medicines should not be used with ZenataneÂ™ unless your doctor tells you it is okay. </span></p>
<p><span class="Bold"></span>Know the medicines you take. Keep a list of them to show to your doctor and pharmacist. Do not take any new medicine without talking with your doctor. </p>
<p><span class="Bold">How should I take ZenataneÂ™? </span></p>
<ul>
<li>
<span class="Bold"></span>You must take ZenataneÂ™ exactly as prescribed. You must also follow all the instructions of the iPLEDGE program. Before prescribing ZenataneÂ™, your doctor will: </li>
<li>explain the iPLEDGE program to you </li>
<li>have you sign the Patient Information/Informed Consent Form (for all patients). Female patients who can get pregnant must also sign another consent form. Â </li>
</ul>
<p><span class="Bold">You will not be prescribed ZenataneÂ™ if you cannot agree to or follow all the instructions of the iPLEDGE program. </span></p>
<ul>
<li>
<span class="Bold"></span>You will get no more than a 30 day supply of ZenataneÂ™ at a time. This is to make sure you are following the ZenataneÂ™ iPLEDGE program. You should talk with your doctor each month about side effects. </li>
<li>The amount of ZenataneÂ™ you take has been specially chosen for you. It is based on your body weight, and may change during treatment. </li>
<li>Take ZenataneÂ™ 2 times a day with a meal, unless your doctor tells you otherwise. <span class="Bold">Swallow your</span><span class="Bold">ZenataneÂ™ capsules whole with a full glass of liquid. Do not chew or suck on the capsule. </span>ZenataneÂ™ can hurt the tube that connects your mouth to your stomach (esophagus) if it is not swallowed whole. </li>
<li>If you miss a dose, just skip that dose. Do <span class="Bold">not </span>take 2 doses at the same time. </li>
<li>If you take too much ZenataneÂ™ or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your doctor or poison control center right away. Â </li>
<li>Your <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> may get worse when you first start taking ZenataneÂ™. This should last only a short while. Talk with your doctor if this is a problem for you. </li>
<li>You must return to your doctor as directed to make sure you donâ€™t have signs of serious side effects. Your doctor may do blood tests to check for serious side effects from ZenataneÂ™. Female patients who can get pregnant will get a pregnancy test each month. </li>
<li>Female patients who can get pregnant must agree to use two separate forms of effective birth control at the same time one month before, while taking, and for one month after taking ZenataneÂ™. <span class="Bold">You must access the iPLEDGE system to answer questions about the program requirements and to enter your two chosen forms of birth control. </span>To access the iPLEDGE system, go to <a href="http://www.ipledgeprogram.com/">www.ipledgeprogram.com</a> or Â call 1-866-495-0654. <p class="First"></p>You must talk about effective birth control methods with your doctor or go for a free visit to talk about birth control with another doctor or family planning expert. Your doctor can arrange this free visit, which will be paid for by the company that makes ZenataneÂ™. <p></p>
<span class="Bold"></span><span class="Bold">If you have sex at any time without using two forms of effective birth control, get pregnant, or miss your expected period, stop using ZenataneÂ™ and call your doctor right away. </span>
</li>
</ul>
<p><span class="Bold"></span><span class="Bold">What should I avoid while taking ZenataneÂ™? </span></p>
<ul>
<li>
<span class="Bold"></span><span class="Bold">Do not get pregnant </span>while taking ZenataneÂ™ and for one month after stopping ZenataneÂ™. See <span class="Bold">â€œWhat is the most important information I should know about ZenataneÂ™?â€? </span>
</li>
<li>
<span class="Bold">Do not breast feed </span>while taking ZenataneÂ™ and for one month after stopping ZenataneÂ™. We do not know if ZenataneÂ™ can pass through your milk and harm the baby. </li>
<li>
<span class="Bold">Do not give blood </span>while you take ZenataneÂ™ and for one month after stopping ZenataneÂ™. If someone who is pregnant gets your donated blood, her baby may be exposed to ZenataneÂ™and may be born with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. </li>
<li>
<span class="Bold">Do not take other medicines or herbal products </span>with ZenataneÂ™ unless you talk to your doctor. See <span class="Bold">â€œWhat should I tell my doctor before taking ZenataneÂ™?â€? </span>
</li>
<li>
<span class="Bold">Do not drive at night until you know if ZenataneÂ™ has affected your vision. </span>Zenatane<span class="Bold">Â™</span> may decrease your ability to see in the dark. </li>
<li>
<span class="Bold">Do not have cosmetic procedures to smooth your skin, including waxing, dermabrasion, or laser procedures, while you are using ZenataneÂ™ and for at least 6 months after you stop. </span>ZenataneÂ™ can increase your chance of <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span> from these procedures. Check with your doctor for advice about when you can have cosmetic procedures. </li>
<li>
<span class="Bold">Avoid sunlight and ultraviolet lights </span>as much as possible. Tanning machines use ultraviolet lights. ZenataneÂ™ may make your skin more sensitive to light.Â Â </li>
<li>
<span class="Bold">Do not share ZenataneÂ™ with other people. </span>It can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and other serious health problems. <span class="Bold">Â </span>
</li>
</ul>
<p><span class="Bold"></span><span class="Bold">What are the possible side effects of ZenataneÂ™? </span></p>
<ul>
<li>
<span class="Bold"></span><span class="Bold">ZenataneÂ™ can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> (deformed babies), loss of a baby before birth (<span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>), <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the baby, and early (premature) births. </span>See <span class="Bold">â€œWhat is the most important information I should know about ZenataneÂ™?â€? </span>
</li>
<li>
<span class="Bold">ZenataneÂ™ may cause serious mental health problems. </span>See <span class="Bold">â€œWhat is the most important information I should know about ZenataneÂ™?â€? </span>
</li>
<li>
<span class="Bold">serious brain problems. </span>ZenataneÂ™ can increase the pressure in your brain. This can lead to permanent loss of eyesight and, in rare cases, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Stop taking ZenataneÂ™ and call your doctor right away if you get any of these signs of increased brain pressure: </li>
<li>bad <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>) </li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> </li>
<li>
<span class="Bold">skin problems. </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> can occur in patients taking ZenataneÂ™. In some patients a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> can be serious. Stop using ZenataneÂ™ and call your doctor right away if you develop <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> (red or inflamed eyes, like â€œpink eyeâ€?), a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> on legs, arms or face and/or sores in your mouth, throat, nose, eyes, or if your skin begins to peel. </li>
<li>
<span class="Bold">stomach area (abdomen) problems. </span>Certain symptoms may mean that your internal organs are being damaged. These organs include the liver, pancreas, bowel (intestines), and esophagus (connection between mouth and stomach). If your organs are damaged, they may not get better even after you stop taking ZenataneÂ™. Stop taking ZenataneÂ™ and call your doctor if you get:</li>
<li> severe stomach, chest or bowel <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> </li>
<li>trouble swallowing or painful swallowing </li>
<li>new or worsening <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> </li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </li>
<li><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> </li>
<li>yellowing of your skin or eyes </li>
<li>dark urine </li>
<li>
<span class="Bold">bone and muscle problems. </span>ZenataneÂ™ may affect bones, muscles, and ligaments and cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your joints or muscles. Tell your doctor if you plan hard physical activity during treatment with ZenataneÂ™. Tell your doctor if you get: </li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> </li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> </li>
<li>broken bone. Tell all healthcare providers that you take ZenataneÂ™ if you break a bone. </li>
</ul>
<p><span class="Bold">Stop ZenataneÂ™ and call your doctor right away if you have <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>. <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> with or without <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> can be a sign of serious <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span>. </span>ZenataneÂ™ may stop long bone growth in teenagers who are still growing. </p>
<ul>
<li>
<span class="Bold">hearing problems. </span>Stop using ZenataneÂ™ and call your doctor if your hearing gets worse or if you have ringing in your ears. Your <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> may be permanent.</li>
<li>
<span class="Bold">vision problems. </span>ZenataneÂ™ may affect your ability to see in the dark. This condition usually clears up after you stop taking ZenataneÂ™, but it may be permanent. Other serious eye effects can occur. Stop taking ZenataneÂ™ and call your doctor right away if you have any problems with your vision or dryness of the eyes that is painful or constant. If you wear contact lenses, you may have trouble wearing them while taking ZenataneÂ™ and after treatment.</li>
<li>
<span class="Bold">lipid (fats and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in blood) problems. </span>ZenataneÂ™ can raise the level of fats and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in your blood. This can be a serious problem. Return to your doctor for blood tests to check your lipids and to get any needed treatment. These problems usually go away when ZenataneÂ™ treatment is finished.</li>
<li>
<span class="Bold">serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>Stop taking <span class="Bold"></span>ZenataneÂ™ and get emergency care right away if you develop <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, a swollen face or mouth, or have trouble breathing. Stop taking ZenataneÂ™ and call your doctor if you get a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or red patches or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> on your legs.</li>
<li>
<span class="Bold">blood sugar problems. </span>ZenataneÂ™ may cause blood sugar problems including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Tell your doctor if you are very thirsty or urinate a lot.</li>
<li>
<span class="Bold">decreased red and white blood cells. </span>Call your doctor if you have trouble breathing, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, or feel weak.</li>
<li>
<span class="Bold">The common, less serious side effects of ZenataneÂ™</span> are <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">chapped lips</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, and <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">dry nose</span> that may lead to <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nosebleeds</span>. Call your doctor if you get any side effect that bothers you or that does not go away. Â </li>
</ul>
<p>These are not all of the possible side effects with ZenataneÂ™. Your doctor or pharmacist can give you more detailed information. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or Dr. Reddys at 1-866-733-3952. </p>
<p><span class="Bold">How should I store ZenataneÂ™? </span></p>
<ul>
<li>Store at 68Â° to 77Â°F (20Â° to 25Â°C). Protect from light<span class="Bold"></span><span class="Bold"></span>. </li>
<li>
<span class="Bold">Keep ZenataneÂ™ and all medicines out of the reach of children. </span>Â </li>
</ul>
<p><span class="Bold">General Information about ZenataneÂ™</span>Medicines are sometimes prescribed for conditions that are not mentioned in Medication Guides. Do not use ZenataneÂ™ for a condition for which it was not prescribed. Do not give ZenataneÂ™ to other people, even if they have the same symptoms that you have. It may harm them.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  This Medication Guide summarizes the most important information about ZenataneÂ™. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about ZenataneÂ™ that is written for healthcare professionals. </p>
<p>You can also call iPLEDGE program at 1-866-495-0654 or visit www.ipledgeprogram.com. </p>
<p><span class="Bold">What are the ingredients in ZenataneÂ™? </span></p>
<p><span class="Bold"></span><span class="Bold">Active Ingredient: </span>isotretinoin</p>
<p><span class="Bold"></span><span class="Bold">Inactive Ingredients: </span>butylated hydroxyanisole, edetate disodium, hydrogenated vegetable oil (Type-I and Type-II), medium chain triglyceride, refined soybean oil and white wax. Gelatin capsules contain gelatin, glycerin, methylparaben, propyl paraben, lake blend blue(LB-332) containing D&amp;C Yellow No.10, FD&amp;C Blue No.1 (for 10 mg), lake blend redÂ  (LB-1574) containing D&amp;C Red No.27, D&amp;C Red No.30 (for 20 mg), lake blend green (LB-333)Â  containing D&amp;C Yellow No.10, FD&amp;C Blue No.1 (for 40 mg), lake blend white (TLB-1774) containing FD&amp;C Blue No.2, titanium dioxide, and opacode black S-1-27794 containing iron oxide black, N-butyl alcohol, propylene glycol, industrial methylene spirit and shellac.<span class="Bold"></span></p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration. </p>
<p>Dilantin is a registered trademark of Warner-Lambert Company LLC.</p>
<p>To reorder additional Medication Guides contact Dr. Reddyâ€™s Customer Service at 1-866-733-3952. </p>
<p>Rx Only</p>
<p></p>
<p>Manufactured by:</p>
<p><span class="Bold">Cipla Limited</span></p>
<p><span class="Bold"></span>Kurkumbh Village</p>
<p>Pune â€“ 413 802 INDIA</p>
<p>Manufactured for:</p>
<p><span class="Bold">Dr. Reddyâ€™s Laboratories Limited</span></p>
<p><span class="Bold"></span>Bachupally â€“ 500 090 INDIAÂ </p>
<p></p>
<p>Issued: 0213</p>
<p></p>
<p>Zenatane is a trademark of Dr. Reddy's Laboratories, Inc. and/or its affiliates.<span class="Bold"></span></p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_b808bb22-e1fc-9da8-3a45-895ca56e2e79"></a><a name="section-14"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First"><span class="Bold">Carton 20 mg</span> : <span class="Bold">30's pack(3x10's)</span></p>
<p><img alt="carton2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=517810a4-76bb-4739-893f-1f2ba94a5d0c&amp;name=carton2.jpg"><span class="Bold"></span></p>
<p><span class="Bold"></span></p>
<p><span class="Bold"></span></p>
<p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<p class="First">NDC 54868-6425-0</p>
<p>20 mg</p>
<p><img alt="package label 20 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=517810a4-76bb-4739-893f-1f2ba94a5d0c&amp;name=6425.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_771e99f1-3de0-3794-b681-aa0c29f90789"></a><a name="section-15"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First"><span class="Bold">Carton 40 mg</span> : 3<span class="Bold">0's pack (3x10's)</span></p>
<p><img alt="carton3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=517810a4-76bb-4739-893f-1f2ba94a5d0c&amp;name=carton3.jpg"><span class="Bold"></span></p>
<p><span class="Bold"></span></p>
<p><span class="Bold"></span></p>
<p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<p class="First">NDC 54868-6426-0</p>
<p>40 mg</p>
<p><img alt="package label 40 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=517810a4-76bb-4739-893f-1f2ba94a5d0c&amp;name=6426.jpg"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZENATANEÂ 		
					</strong><br><span class="contentTableReg">isotretinoin capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6425(NDC:55111-136)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOTRETINOIN</strong> (ISOTRETINOIN) </td>
<td class="formItem">ISOTRETINOIN</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROGENATED SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEDIUM-CHAIN TRIGLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WHITE WAX</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 27</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">R136</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6425-0</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202099</td>
<td class="formItem">05/16/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZENATANEÂ 		
					</strong><br><span class="contentTableReg">isotretinoin capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6426(NDC:55111-137)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOTRETINOIN</strong> (ISOTRETINOIN) </td>
<td class="formItem">ISOTRETINOIN</td>
<td class="formItem">40Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROGENATED SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEDIUM-CHAIN TRIGLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WHITE WAX</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">R137</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6426-0</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202099</td>
<td class="formItem">05/16/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-6425, 54868-6426)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3bb8e94b-5395-4d6b-a835-12aa4570a5dd</div>
<div>Set id: 517810a4-76bb-4739-893f-1f2ba94a5d0c</div>
<div>Version: 1</div>
<div>Effective Time: 20140822</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
